

Corporate Social Responsibility

2009 Report

"Acting ethically and responsibly
for the patient"



Contents

- Interview with Christopher A. Viehbacher and Gilles Lhernould
- Strategy
 - ▶ A global healthcare leader
 - ▶ Placing Corporate Social Responsibility (CSR) at the core of the Group's strategy
 - ▶ Identifying CSR challenges, establishing priorities and adapting structures
- Performance
 - ▶ Patient 21
 - ▶ Ethics 21
 - ▶ People 21
 - ▶ Planet 21
- Appendices
 - ▶ Social and Environmental Indicators
 - ▶ How Data are Reported: Methodological Note
 - ▶ Statutory Auditors' Review Report
 - ▶ Glossary

Transformation

In 2009, sanofi-aventis initiated a transformation program to become a diversified, global healthcare company. This transformation affected the Company's approach to sustainability.

As an expression of this new direction, the Sustainability Report has also been transformed:

- It is now called the CSR (Corporate Social Responsibility) Report;
- For the first time ever, it will be available on-line instead of in print (this translates into savings of 9.2 tons in CO₂ emissions);
- The report focuses on important CSR challenges identified by materiality testing;
- More in-depth information is provided on the [Group's CSR website](#).

INTERVIEW

Christopher A. Viehbacher,
Chief Executive Officer



Gilles Lhernould,
Senior Vice President
Corporate Social Responsibility



“Social responsibility is part of the DNA of sanofi-aventis.”

What new developments took place in 2009?

Christopher A. Viehbacher (CV): This has been a pivotal year. We set out decisively on a new course toward sustainable growth and set our sights on becoming a global, diversified leader in healthcare, focused on patients' needs. To reach this objective, we identified three areas in which significant progress was made in 2009. First, we created a new organization to stimulate innovation in research and development. Second, we opened the Group to new external partnerships through 33 acquisitions and agreements. Lastly, we undertook the company's transformation to develop new platforms for growth.

Gilles Lhernould (GL): The transformation is also reflected in our sustainability approach, which was adapted to meet the new challenges before us. More international in scope, with particular emphasis on what our stakeholders have to say, the sustainability approach is now integrated into the newly-created Corporate Social Responsibility (CSR) function.

What is the role of the new CSR function?

CV: Our priority has always been, and will continue to be, acting in a socially and ethically responsible manner as a healthcare partner. By creating a CSR function, we are asserting our determination to place the patient at the center of our commitment. Corporate Social Responsibility is a critical part of our strategy because it not only drives our performance; it improves our performance.

GL: Our goal is to bring together, within the CSR function, all the Group's major initiatives in the economic, social and environmental fields, access to medicines, diversity and humanitarian partnership. We want to rise to the challenge of supporting all sanofi-aventis entities in addressing the major CSR issues, and we want to organize cross-functional projects. For this to happen, it is important to improve awareness among all employees about Corporate Social Responsibility. This above all requires being even more attentive to our stakeholders and aiming for transparency in our approach, especially with respect to issues such as access to healthcare, product safety, counterfeit drugs, and social and ethical

transformations in research. I should not overlook respect and protection of the environment as well, since they are essential for the health of communities and the planet.

Is this approach compatible with your objectives for growth and profitability?

CV: Yes, without a doubt. I am truly convinced that the CSR approach contributes to the Group's performance: it allows us to minimize risks even further and encourages us to innovate; it gives us incentives to explore different healthcare options worldwide and turn to new therapeutic solutions that are tailored to meeting patients' needs. In addition, the CSR approach contributes to optimizing our internal operations.

GL: From my perspective, CSR is more than a commitment; it's an opportunity. CSR enables us to choose the most sustainable growth vectors for sanofi-aventis, generating value for the patient and for the men and women who work for the Group, and who are proud to give a sense of meaning to their jobs.

Strategy

Corporate Social Responsibility (CSR) lies at the core of sanofi-aventis' business. Being a healthcare partner involves promoting social progress, economic development and respect for the environment as well as acting ethically and responsibly. The CSR approach places the patient at the center of the Group's business activities. It is an approach that constantly seeks a balance between access to healthcare, innovation, respect for intellectual property rights and sustainability of healthcare systems. As an integral part of the Group's strategy and values, CSR is essential to our vision for the future: delivering sustainable growth.

A GLOBAL HEALTHCARE LEADER

PLACING CORPORATE SOCIAL RESPONSIBILITY
AT THE CORE OF THE GROUP'S STRATEGY

IDENTIFYING CSR CHALLENGES, ESTABLISHING
PRIORITIES AND ADAPTING STRUCTURES

A GLOBAL HEALTHCARE LEADER

As a healthcare company with a diversified portfolio, an extensive geographic presence and a large number of employees, sanofi-aventis has important economic, social and environmental responsibilities to its stakeholders.

- Approximately 105,000 employees in 110 countries
- A diversified product portfolio with prescription drugs, consumer healthcare products (OTC) and generics
- N° 1 in emerging markets⁽¹⁾ with a balanced and long-established presence
- A global leader in human vaccines
- A global leader in animal health
- 2009 sales: 29.3 billion euros, with growth of 6.3%⁽²⁾
- 33 acquisitions and partnerships in 2009

Sanofi-aventis' ambition is to become a diversified global healthcare company focused on the patient's needs.

To reach this objective and deliver sustainable growth, the Group is focusing on three key themes:

- Increasing innovation in Research and Development;
- Seizing external growth opportunities;
- Adapting Group structures to meet future challenges.

Sanofi-aventis relies on its core strengths in the healthcare field, with five key platforms for growth:

- Emerging markets;
- Vaccines;
- Consumer healthcare products;
- The diabetes drugs portfolio;
- Innovative products.

(1) Worldwide excluding the United States, Canada, Western Europe (France, Germany, United Kingdom, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxemburg, Sweden, Portugal, the Netherlands, Austria, Switzerland, Ireland, Finland, Norway, Iceland, Denmark), Japan, Australia and New Zealand.

(2) Compared to 2008 published data.

PLACING
CORPORATE
SOCIAL
RESPONSIBILITY AT
THE CORE OF THE
GROUP'S STRATEGY

The CSR approach is an integral part of the sanofi-aventis strategy and supports the Group's growth and development while upholding the values on which it is founded. The Group expresses its responsibility as a global healthcare company through its CSR approach, which since 2008 has been based on four key areas that take as their reference the **United Nations "Agenda 21"** blueprint for sustainability in the 21st century.

- ▶ **Patient 21:** the patient at the center of the Group's business activities
- ▶ **Ethics 21:** ethics in action
- ▶ **People 21:** employees and local communities
- ▶ **Planet 21:** environmental performance

PILOTING A CROSS-FUNCTIONAL APPROACH

The Sustainability Department, which since October 2009 has been part of the CSR function, oversees the operational implementation of the approach in collaboration with a steering committee, called the **Group Sustainability Committee (GSC)**. The GSC is made up of representatives from corporate and regional functions. Because they interface with members of the Group Management Committee, these members are the driving force in policy implementation for both employees and external stakeholders. Their role is to determine challenges, identify priority commitments and increase awareness of the approach as well as share information about CSR initiatives in the field.

In 2009, the CSR approach entered a new phase with the further expansion of its international network to all affiliates as well as growing stakeholder involvement.

As a result, sanofi-aventis has developed a correspondent network across all Group regions and functions, on all continents. The correspondents play an essential role in implementing the Group's CSR approach to give rise to initiatives and responses that are in line with stated expectations.

To further implement CSR across all regions using the network, the Group has established two objectives for 2010:

- Develop the necessary tools to roll out the CSR approach locally;
- Maintain the momentum generated by the network and establish a means to share best practices.

From Sustainability to Corporate Social Responsibility (CSR)

In late 2009, the sanofi-aventis Sustainability Department became part of the newly established Corporate Social Responsibility function. This new function came about

in response to the Group's decision to bring together all the major initiatives in the field of economic, social and environmental responsibility. The CSR function encompasses access to medicines, humanitarian partnership, sustainability, diversity/disability, and Group initiatives designed to help employees and their families.

The Senior Vice President of Corporate Social Responsibility reports directly to the Chief Executive Officer of sanofi-aventis, as a clear illustration of the strategic importance of this new role in ensuring the overall consistency in all the Group's CSR initiatives.

INCREASING AWARENESS OF CSR CHALLENGES

Numerous initiatives were organized in 2009 to increase awareness of CSR challenges among all Group employees and to encourage them to participate in the Group's approach on a daily basis.

The Sustainability Department is increasingly and regularly taking part in training seminars organized by the Human Resources Department.

In addition, a large number of affiliates participated in the 2009 Sustainability Week. This Group initiative, introduced in 2007, is becoming an annual event that generates an increasing number of contributions from employees.

Another important milestone was the complete overhaul of the Intranet Sustainability website, which has been redesigned and expanded. This site provides an important means to enhance and communicate about the approach. The Sustainability Department also posts monthly e-newsletters and in late 2009 created an in-house blog to encourage interactive exchange with employees.

Standards and controls: a fully integrated CSR approach

The sanofi-aventis CSR approach is based on a cross-functional method designed to ensure full integration at every level in order to further minimize risk:

- The Group complies with the most widely recognized **international CSR standards**;
- Additionally, various external standards are used to develop internal guidelines such as codes, charters and procedures;
- Sanofi-aventis implements these guidelines and monitors their application across the entire Group.

For more information, see website

sanofi-aventis

2009 Document de Référence:
section 3.2, *Rapport du Président du Conseil d'administration*
2009 Form 20-F:
Part II, Item 15

A recognized CSR approach

In 2009, sanofi-aventis was once again recognized and rewarded by being listed on the most important global indices for Corporate Social Responsibility (CSR) performance.



▶ For more information, see website
[sanofi-aventis](#)

IDENTIFYING CSR CHALLENGES, ESTABLISHING PRIORITIES AND ADAPTING STRUCTURES

In 2009, sanofi-aventis modified the Group's CSR approach by giving greater weight to stakeholders' expectations in the reporting framework. This decision was part of the transformation process designed to make the Group more open to external growth. Working alongside consultants from Deloitte, the Group also adapted its approach to CSR reporting.

IDENTIFYING CSR CHALLENGES TO FURTHER LIMIT RISKS

For nearly ten years, analysts and investors have included the financial impact of businesses' CSR performance in the evaluation of opportunities and risks. This approach is consistent with economic regulatory reforms⁽¹⁾, which have gradually expanded the definition of significant risks to include CSR challenges.

Sanofi-aventis carefully monitors the CSR challenges that are currently considered to be significant from a financial and extra-financial viewpoint in order to anticipate any new developments.

For more information, see website

▶ **sanofi-aventis**
2009 Document de Référence: section 3.1.10, Facteurs de risques
2009 Form 20-F: Part I, Item 3.D

INVOLVING STAKEHOLDERS TO BETTER ESTABLISH PRIORITIES

To complement the process used to identify CSR challenges, the Group has adopted the approach recommended by the GRI (Global Reporting Initiative) and AA1000 standards. Moreover, in 2009 the Group conducted a new materiality test. The key CSR challenges for sanofi-aventis were identified based on the Group's strategy and the reporting structure from previous years, and according to the GRI and LEEM (the French pharmaceutical companies association) indicators. These challenges were then further qualified based on two groups of criteria:

- Those specific to sanofi-aventis and to the pharmaceutical sector from a business perspective: the Group's strategy and expertise, benchmarking from peer companies and outside expertise;
- *Those external to sanofi-aventis and to the pharmaceutical sector in terms of stakeholder expectations: stakeholder consultation (employee representatives, patient organizations, healthcare professionals, NGOs, rating agencies, etc.) press reviews, questionnaire analysis (SAM, EIRIS, Vigeo) and assessments by financial and extra-financial analysts (CSR-Europe).**

WEB ▶ [GRI and AA1000 standards](#)

⁽¹⁾See in particular the Sarbanes-Oxley Act in the United States, the NRE Law (Nouvelles Régulations Économiques) in France and the 2004 debate on the Operating and Financial Review (OFR) in the United Kingdom.

* The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).

Strategy


IDENTIFYING CSR CHALLENGES, ESTABLISHING PRIORITIES AND ADAPTING STRUCTURES

ADAPTING THE CSR REPORTING STRUCTURE

The materiality test made it possible to define and prioritize **CSR challenges** for the Group. The reporting structure was adapted as follows:

- The CSR Report covers the most significant challenges, with more in-depth information available on the sanofi-aventis CSR website;
- Other challenges are addressed in detail on the Group's CSR website.

MATERIALITY TEST




Performance

As a diversified global healthcare company, sanofi-aventis bases its CSR approach on four key areas, which provide the foundation for the Group's social responsibility:

- Patient 21: the patient at the center of the Group's business activities
- Ethics 21: ethics in action
- People 21: employees and local communities
- Planet 21: environmental performance


The Group's ambition is to act in an ethical and responsible way to serve health. This requires us to comply with ethics rules vis-à-vis all stakeholders. It means we capitalize on the talents of our employees and support them during the Group's transformation. And lastly it means that we seek to minimize the environmental impact of the Group's activities. In 2009, this sustainable approach was further strengthened thanks to many different initiatives.



PATIENT 21

The patient at the center of the Group's commitments

Sanofi-aventis upholds its commitment to health and prevention by acting in an ethical and responsible manner. This commitment is built on a social contract between patients and the Group. Respecting this contract requires careful consideration of healthcare needs and expectations; it necessitates placing the patient at the center of our business strategy. The Group's commitment takes shape in programs that promote access to healthcare, for both medicines and vaccines. There are many ways to be attentive to needs: paying greater attention to neglected tropical diseases, transforming our approach to Research and Development (R&D), and seeking innovation in sanofi-aventis' relationship with patients. Ultimately, it means being ever more vigilant about product quality, safety and the services we provide to patients.



For a group like sanofi-aventis, which is focused on research, production and bringing healthcare products to market, enabling individuals to exercise their right to health requires facilitating access to quality medicines and vaccines. As it continued to meet this challenge in 2009, the Group emphasized its development model, which is based on a diversified portfolio: a broad range of prescription medicines, consumer healthcare products (OTC) and generic medicines and vaccines. In addition, sanofi-aventis implements programs that promote access to healthcare for people in developing countries and for disadvantaged groups and those with inadequate healthcare coverage in industrialized countries. This approach contributes to the sustainability of healthcare systems and ensures the Group's lasting growth.

The right to health: **access to healthcare**

OUR COMMITMENTS

Some 80% of the global population has no access to appropriate healthcare. The ambition pursued by sanofi-aventis is to facilitate access to its medicines and vaccines for as many patients as possible.

PROMOTING ACCESS TO HEALTHCARE IN **DEVELOPING COUNTRIES**

PROMOTING ACCESS TO HEALTHCARE IN **INDUSTRIALIZED COUNTRIES**

CONTRIBUTING TO THE SUSTAINABILITY OF **HEALTHCARE SYSTEMS**

TAKING PART IN COMBATING **NEGLECTED TROPICAL DISEASES:**
VALUABLE EXPERTISE

PATIENT 21


PROMOTING ACCESS TO HEALTHCARE IN DEVELOPING COUNTRIES

Considering that improving access to medicines and vaccines in developing countries contributes to breaking the poverty/illness cycle, sanofi-aventis takes an approach that goes well beyond providing financial support for development programs. The Group focuses on diseases for which it has genuine expertise and develops programs to facilitate access to healthcare. These programs cover a wide range of initiatives, from conducting specific research projects to ensuring that essential medicines are available.



Access to medicines and vaccines in developing countries: a commitment and an investment

OUR ACTIONS



- Developing better adapted malaria treatments ▶
- Contributing to the treatment of diabetes ▶
- Promoting access to quality vaccines for as many people as possible ▶
- Coordinating the response to humanitarian emergencies ▶

▶ ACCESS TO HEALTHCARE PROGRAMS IN 2009

PROMOTING ACCESS TO HEALTHCARE IN DEVELOPING COUNTRIES

OUR ACTIONS (part one)

Developing better adapted malaria treatments

Malaria is the most widespread transmissible disease in the world and, like HIV/AIDS and tuberculosis, represents a major public health challenge. Because **ASAQ** (Coarsucam® or artesunate-amodiaquine Winthrop®) has obtained WHO prequalification, sanofi-aventis was able to distribute its new malaria treatment in 24 African countries in 2009. More than 23 million treatments were distributed using a differentiated pricing policy. Since the Group favors local production as much as possible, these treatments were manufactured in Morocco. In addition to providing ASAQ to ensure comprehensive treatment for malaria, a number of **awareness-raising campaigns** have been organized. The Schoolchildren against Malaria initiative enabled 40,000 children in Côte d'Ivoire, Ghana and Burkina Faso to learn more about the disease. Another initiative focused on training healthcare personnel for a global approach to combating malaria, with sessions held in Burundi, Congo and Benin. During 2009, in certain Asian and Latin American countries, the Group also launched projects to introduce ASAQ into national malaria programs.

Contributing to diabetes treatment

Long considered to be a disease found in developed countries, today diabetes is becoming a disease of developing countries as well. In response to this raging epidemic, sanofi-aventis organizes regional initiatives, especially in Asia and Africa. Innovation for Life was introduced in the Philippines and Indonesia in 2009. This program promotes access to innovative therapies such as insulin glargine (Lantus®) for diabetic patients who without this program would not have access to this treatment. It includes an adapted pricing policy and services for patients and healthcare professionals. In the span of a few months, more than 2,000 new Indonesian patients were able to take advantage of this initiative. In Africa, Latin America and Asia, the Group also supports pilot projects created by Santé Diabète Mali and Handicap International. These projects cover needs ranging from diabetes prevention to medical care and education for diabetics. In addition, in 2009 the Group decided to invest in China so that Lantus® SoloSTAR® can be manufactured locally. With a production capacity of up to 50 million units per year, this new investment will make it possible to improve diabetes treatment in China.



VIDEO
Schoolchildren Against Malaria

WEB ▶ *The Impact Malaria Program*

MALARIA: IN 2009, MORE THAN

23 million

DOSES OF ASAQ WERE SOLD AT
DIFFERENTIATED PRICES IN AFRICA

▶ For more information, see website
sanofi-aventis
Access to Medicines



VIDEO
Diabetes: A Developing Disease

PATIENT 21

PROMOTING ACCESS TO HEALTHCARE IN DEVELOPING COUNTRIES

OUR ACTIONS (part two)

Promoting access to high-quality vaccines for as many people as possible

Access to vaccines is another important component in the Group's efforts to support the right to health. Its objective is to be able to meet the need for high-quality vaccines at affordable prices, a mission that sanofi pasteur, the vaccines division of sanofi-aventis, has been upholding for many years through its differentiated pricing policy. The 2009 acquisition of Shantha Biotechnics further enhanced this approach. Shantha is an Indian vaccines producer whose acquisition expands the Group's portfolio of essential vaccines that are both high quality and affordable.


*At the same time, in 2009 the Group continued its efforts to create the first dengue fever vaccine, which is currently in Phase IIb of development.**

Local production is another Group priority. In 2009, sanofi-aventis began building a new manufacturing plant in Mexico that will make it possible to produce up to 25 million doses of influenza vaccine by 2013.

Coordinating the response to humanitarian emergencies

One of the missions of the CSR-Humanitarian Partnership Department is to coordinate the Group's response to humanitarian emergencies. This department also develops partnerships to provide long-term development aid for the most disadvantaged populations.

For more information, see website
 **sanofi-aventis**
 CSR-Humanitarian Partnership



VIDEO
 Dengue Fever:
 An Under-diagnosed Disease

A PORTFOLIO OF **18** VACCINES
 UNDER DEVELOPMENT (as of February 10, 2010)



Investing in training in Africa

740,000
 BOXES OF MEDICINES AND
600,000
 DOSES OF VACCINES WERE DONATED IN 2009 TO
63 COUNTRIES

** The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).*

PATIENT 21

PROMOTING ACCESS TO HEALTHCARE IN DEVELOPED COUNTRIES

OUR ACTIONS

Strengthening patient assistance programs


In the United States, the Patient Assistance Program (PAP) provides access to Group medicines at reduced prices, and even free of charge, for qualifying patients and their families. In 2009, under these programs, the retail value of products provided for free exceeded \$200 million. One of the key changes in 2009 was the adjustment to income requirements to allow more patients to be eligible, and several changes were made to the application process, making it easier to apply to the program. A new website was also created to help more patients find out about these programs.

Another program developed by sanofi-aventis, **PACT+™** (Providing Access to Cancer Therapy), provided assistance to over 4,000 U.S. patients in 2009.

IN 2009,

160,000

U.S. PATIENTS RECEIVED OVER 30 SANOFI-AVENTIS MEDICINES AT REDUCED PRICES, OR FOR FREE

For more information, see website
 **sanofi-aventis**
 Patient Assistance Program

PPA: a program for prescription assistance

Reducing the time to market for medicines

Improving access to healthcare also involves close cooperation with healthcare authorities in charge of marketing authorizations in order to reduce the time required to bring new products to market, so that patients may benefit from these medicines as rapidly as possible. In Japan, where time to market is two to three times longer than in Europe, sanofi-aventis introduced a program called Minimize Drug Lag in 2009.



PATIENT 21

CONTRIBUTING TO THE SUSTAINABILITY OF HEALTHCARE SYSTEMS

Sanofi-aventis' mission is to provide quality medicines and vaccines to those who need them. In order to achieve this goal, the Group is committed to seeking a balance between access to healthcare, support for innovation, respect for intellectual property rights and the sustainability of healthcare systems.

OUR ACTIONS



- Diversifying in order to remain a long-term partner in healthcare systems ▶
- Supporting intellectual property and innovation: acting in the patient's interest ▶
- Contributing to controlling healthcare costs through generic medicines ▶
- Using vaccines to reduce the burden of disease ▶
- Being prepared to meet health challenges related to climate change ▶

CONTRIBUTING TO THE SUSTAINABILITY OF HEALTHCARE SYSTEMS

OUR ACTIONS (part one)

Diversifying in order to remain a sustainable partner in healthcare systems

The diversification strategy adopted by sanofi-aventis is intended to ensure a broader, more accessible range of products to patients. In 2009, a number of acquisitions enhanced this approach, expanding and bringing greater balance to the Group's product portfolio. Prescription medicines, vaccines, consumer healthcare products (OTC) and generics make up sanofi-aventis' product portfolio, with a balanced presence on both traditional and emerging markets. Thanks to this diversification, which ensures sustainable growth for the Group, it is better poised to meet the needs of healthcare systems worldwide and to remain a dependable long-term partner.

Supporting intellectual property and innovation: acting in the patient's interest

Sanofi-aventis considers that defending intellectual property rights is not only one of the pillars of the healthcare industry, but essential for the Group's future. Without patents, it is impossible to ensure the sustainability of investments necessary for innovation, and innovation is the driving force in providing therapeutic solutions to meet patients' needs. However, this principle must be applied with a degree of flexibility, specifically as it concerns facilitating access to medicines and vaccines. *Under certain circumstances, such as in the case of ASAQ to treat malaria, the Group deliberately chooses to waive its patent rights in order to increase the accessibility of a drug.**

MORE THAN

500 millionPEOPLE IMMUNIZED WITH
SANOFI-AVENTIS VACCINES
WORLDWIDE

* The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).

CONTRIBUTING TO THE SUSTAINABILITY OF HEALTHCARE SYSTEMS

OUR ACTIONS (part two)

Contributing to controlling healthcare costs through generic medicines

The cost of medicines is a key factor in the equilibrium of healthcare systems, from a financial perspective as well as for access to care. One of the ways in which sanofi-aventis addresses this challenge is by offering a diversified portfolio of generic medicines.

As an integral part of the Group's strategy, the portfolio includes generic versions of sanofi-aventis products (sold historically under the Winthrop brand) as well as generics of compounds developed by other pharmaceutical companies whose patent rights have expired. Three major acquisitions strengthened the Group's positioning in 2009: **Medley, Kendrick and Zentiva**. Thanks to these acquisitions, sanofi-aventis is now a leader in generics.

LEADER IN GENERICS MANUFACTURING



Using vaccines to reduce the burden of disease

Developing vaccines is another way to contribute to the sustainability of healthcare systems. Vaccines are often an essential complement to therapeutic strategies because they prevent diseases, reducing the need for treatment. Sanofi-aventis is a global leader in human vaccines. The Group's vaccines portfolio provides protection against 20 infectious diseases. More than 1.6 billion doses of vaccines are produced each year to immunize over 500 million people worldwide.

EACH YEAR, THE GROUP PRODUCES

1.6 billion

DOSES OF VACCINES

Being prepared to meet health challenges related to climate change

*Sanofi-aventis has identified health challenges related to climate change. Cold snaps and heat waves, water contamination, insect-borne diseases, ozone depletion, extreme weather: the Group has inventoried the diseases that are likely to result from these climate changes and is preparing, in its fields of expertise, to anticipate their potential health consequences.**

CLIMATE CHANGE AND HEALTH: THE GROUP'S POSITION

* The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).

PATIENT 21

By devoting investments to highly prevalent neglected tropical diseases, sanofi-aventis confirms its patient-centric strategy with the goal of taking an active part in combating diseases such as Human African trypanosomiasis (sleeping sickness), leishmaniasis, Buruli ulcer and Chagas disease. The Group has developed specific programs for these diseases, especially in R&D, and has established a longstanding partnership with the World Health Organization (WHO).

HOW DOES THE WHO DEFINE A "NEGLECTED" DISEASE?

TAKING PART IN COMBATING NEGLECTED TROPICAL DISEASES: VALUABLE EXPERTISE

OUR ACTIONS

Pursuing the partnership with the WHO to deliver three effective medicines for sleeping sickness

Human African trypanosomiasis, or sleeping sickness, is one of the most complex, and one of the most neglected, of all endemic tropical diseases. Today, three of the four drugs used to treat this disease are produced by sanofi-aventis.

In 2001, sanofi-aventis initiated a partnership with the WHO and extended it in 2006 (investing a total of \$50 million over a period of ten years). In 2009, sanofi-aventis delivered more than 104,000 bottles of eflornithine (Ornidyl®), over 20,000 vials of Pentacarinat® 300 mg and nearly 47,000 vials of melarsoprol (Arsobal®). According to the WHO, this means 10,000 patients received treatment, saving 10,000 lives in 2009 and 140,000 since the beginning of the partnership.

Developing a new drug for the treatment of sleeping sickness

In 2009, important strides were made regarding sleeping sickness. The Group entered into a collaboration agreement with the Drugs for Neglected Disease initiative (DNDi) for the development, manufacture and distribution of a promising new treatment for this disease: fexinidazole. This new medicine may be able to replace complex and often poorly tolerated treatments with a simpler drug, which can be taken orally. Sanofi-aventis will be responsible for the industrial development of fexinidazole, which entered Phase I of clinical development in September 2009.

IN 2009, 10,000 LIVES WERE SAVED THANKS TO SANOFI-AVENTIS DRUGS TO TREAT SLEEPING SICKNESS AND

140,000 lives

HAVE BEEN SAVED SINCE THE INCEPTION OF THE DNDi PARTNERSHIP



For more information, see website **sanofi-aventis** Access to Medicines

PATIENT 21


Solidly rooted in the values of sanofi-aventis, innovation is fundamental to our transformation process. The Group is guided by the ability to provide solutions for unmet medical needs and relies on innovation as a mindset that involves continuously asking questions. From research to marketing, from production to sales, all the functions developed new approaches to reach this shared objective in 2009. The driving force behind the Group's resolve to innovate is the benefit for patients, yet other factors constantly reinforce this commitment, from competition within the industry to the partial reduction of reimbursement for certain products and the loss of exclusive rights to exploit patents between now and 2013.

INNOVATION: A PRIORITY

OUR COMMITMENTS

The objective is for innovation to become a mindset for all employees within all Group functions, from R&D to commercialization, for the benefit of patients and sanofi-aventis.

OUR ACTIONS



- Accelerating research and development of new medicines and vaccines ▶
- Promoting innovation in industrial processes ▶
- Meeting patients' expectations with new services ▶

TWO SANOFI-AVENTIS PRODUCTS ARE AMONG THE **TOP 10** MEDICAL INNOVATIONS SELECTED BY *TIME MAGAZINE* IN THE UNITED STATES: AN INFLUENZA A(H1N1) VACCINE AND A CANDIDATE HIV VACCINE

INNOVATION: A PRIORITY

OUR ACTIONS

Accelerating research and development of new medicines and vaccines

To speed up the development of innovative compounds and vaccines, strategic partnerships are an essential component of R&D policy so that the Group is prepared to take advantage of important value-added development opportunities for patients. To reach this goal, **R&D underwent extensive reorganization** in 2009. The year 2009 was marked by a sizeable increase in the number of external ventures, with 33 acquisitions or partnerships or in-licensing deals, including 20 R&D agreements. Today, 55% of the Group's clinical portfolio is developed through external R&D. In particular, these endeavors allowed the Group to **consolidate its positions in oncology** with BiPar Sciences and Exelixis. Another benefit of external growth is that it allows sanofi-aventis to break into new therapeutic areas, such as ophthalmology with the acquisition of FOVEA.

Promoting innovation in industrial processes

Because innovation is an integral part of a global approach to drug development, in 2009, Industrial Affairs created the Industrial Development and Innovation Department. This new department acts as an interface between R&D and the industrial process to improve the dynamics of product life cycle management thanks to innovations in processes and technologies for medicines and medical devices. In order to recognize the Group's top industrial innovations new "**Innovation Awards**" were established.

Meeting patients' expectations with new services

Another area in which the Group innovates concerns its relationships with patients. In 2009, the Pharmaceutical Customer Solutions Department worked on several projects designed to improve patient services. One example in the United States was the GoMeals™ Program. Sanofi-aventis U.S. developed an iPhone application that helps diabetics make healthy food choices and better manage glucose intake. In addition, in 2009, with the support of regional platforms, the Group launched an initiative called the Ide@Box throughout affiliates worldwide. This interactive suggestion box allows employees to propose initiatives that will improve relationships with patients and healthcare professionals. At the end of 2009, four weeks after its global launch, Ide@Box had received more than 500 suggestions from employees from around 40 countries. Prizes for the best ideas will be presented during an awards ceremony in 2010.

▶ PRIMARY PARTNERSHIPS
AND ACQUISITIONS DRIVING
INNOVATION IN R&D



Innovation Awards

PATIENT 21

Providing support for patients and their caregivers during an illness is a top priority for sanofi-aventis. A distinction must be made between general disease awareness and information programs, and those that are designed specifically for patients who are receiving treatment. Sanofi-aventis' ongoing relationships with patient organizations strengthen our programs. In 2009, the Group organized and implemented a number of initiatives in diabetes and oncology. One noteworthy development is the growing involvement of healthcare professionals and health authorities in patient support and disease prevention programs. Taking a concerted and transparent approach to which sanofi-aventis contributes, they serve both patients and healthcare systems.

More than 270
WEBSITES FOR THE GENERAL PUBLIC

INFORMATION AND PATIENT EDUCATION

OUR COMMITMENTS

Developing a quality relationship with patients is very important for sanofi-aventis. This relationship is built through the Group's attention to individuals and patients through prevention, information and educational initiatives, in coordination with healthcare systems.

OUR ACTIONS



- Consolidating and expanding patient support programs ▶
- Improving awareness about diseases ▶
- Collaborating with patient organizations ▶

INFORMATION AND PATIENT EDUCATION

PATIENT 21

OUR ACTIONS

Consolidating and expanding patient support programs

Patient support programs are active in dozens of countries. The primary innovations in 2009 concern efforts focusing on diabetes, for which the Group has developed novel regional initiatives.

Also, sanofi-aventis has patient support programs for vaccines. For example, in Vietnam, a new patient and healthcare professional information and education program was created in 2009 to raise awareness about rabies, meningitis and influenza vaccines.

Improving awareness about diseases

The disease awareness programs developed by the Company are designed to inform the public, prevent disease and raise awareness about disease symptoms and treatments.

In 2009, diabetes programs were supported in Mexico with "El Tour de la Vida" and in the United States with the Diabetes National Alliance initiative. The Group is also very active in the field of cancer and, in 2007, initiated a television program in the U.S. about women and cancer, called Frosted Pink. This popular television program, renamed Kaleidoscope in 2009, was again viewed by a large audience. In addition, the Company supported a number of awareness initiatives about malaria that were adapted to target every segment of the healthcare chain.

Collaborating with patient organizations

Sanofi-aventis works with patient organizations in over 35 countries and acts as a partner to regional and international associations. The focus of these partnerships may fall within one of the Group's therapeutic areas of expertise (cardiovascular diseases, thrombosis, metabolic disorders, oncology, central nervous system disorders, internal medicine) or it may relate to general topics (for example, fair access to treatment) that are important issues for all patients, regardless of their condition or disease. The list of European-based patient organizations receiving support from sanofi-aventis is updated regularly on the Group's website.



▶ FOCUS
"Comida Que Cuida"

▶ DISEASE AWARENESS PROGRAMS

"The lives of patients: a daily challenge."

▶ For more information, see website
sanofi-aventis
Information and patient education

PATIENT 21

One of sanofi-aventis' principal missions is to ensure the safety and quality of the Group's products. Pharmacovigilance seeks to constantly improve the risk/benefit ratio for a medicine or vaccine that is already on the market and being used by patients. This mission engages the Group's responsibility toward patients.


WHAT IS PHARMACOVIGILANCE?

PHARMACOVIGILANCE: A SAFETY IMPERATIVE

OUR COMMITMENTS

The Group strives to constantly improve risk management related to the use of its medicines and vaccines. This commitment requires the implementation of an appropriate global and local organization for this purpose. Pharmacovigilance is the focus of increasing attention from health authorities, as demonstrated by the fact that the number of inspections within the Group doubled between 2008 and 2009.

OUR ACTIONS



- Implementing a new risk management plan ▶
- AWARE: a new pharmacovigilance/epidemiology database ▶
- Continuing to generate synergies with sanofi pasteur ▶
- Developing an innovative pharmacovigilance program in Africa ▶

PHARMACOVIGILANCE: A SAFETY IMPERATIVE

OUR ACTIONS (part one)

Implementing a new risk management plan

*In 2009, the Group pursued and improved its product surveillance approach through a dedicated organization providing the necessary expertise and resources. This organization is in charge of implementing and monitoring risk management plans, which are prepared for the submission of marketing registration dossiers as well as for products already on the market. They are also important during earlier phases of product development. Implemented at all relevant Group affiliates, risk management plans are designed to formalize, in exact terms, the procedures to identify, evaluate and report a product or device's adverse effects, and to mitigate them. These iterative processes are especially useful in improving knowledge of the product and related risks, and anticipating any action that may need to be taken after the product is marketed, such as organizing clinical or epidemiological safety trials and taking measures to minimize risks. This approach incorporates continually assessing a product's risk/benefit ratio.**

This process makes it possible to, first, evaluate the incidence and prevalence of diseases, and second, to determine potential or identified risks in relation to medicines and vaccines.

AWARE: a new pharmacovigilance/epidemiology database

Pharmacovigilance databases are vital tools because they collect information concerning any potential connection between a medicine and an adverse effect.

In 2009, sanofi-aventis launched a new global database called AWARE. This unique system, which replaced two previous databases, makes it possible to manage pharmacovigilance data generated by the affiliates and by the Group Pharmacovigilance Division. Designed to meet European regulatory requirements (EMEA), the U.S. requirements (FDA), and Japanese standards (PMDA), AWARE offers new flexible functionalities that makes it possible to adapt to new regulatory developments.

WHAT IS A RISK MANAGEMENT PLAN ?

APPROXIMATELY

800

PEOPLE DEVOTED TO PHARMACOVIGILANCE IN THE

169 COUNTRIES WHERE SANOFI-AVENTIS MARKETS ITS PRODUCTS

** The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).*

PHARMACOVIGILANCE: A SAFETY IMPERATIVE

OUR ACTIONS (part two)

Continuing to generate synergies with sanofi pasteur

The Pharmacovigilance departments at sanofi-aventis and sanofi pasteur are working together to coordinate their monitoring activities in connection with medicines and vaccines. Efforts to create synergies between the departments, which began with the affiliates, are designed to optimize local Pharmacovigilance organizations to verify that they are compliant with specific country regulations, while also ensuring the utmost in product safety.

Developing an innovative program for pharmacovigilance in Africa

In 2009, in partnership with Medicines for Malaria Venture (MMV), sanofi-aventis launched the largest pharmacovigilance study of an antimalarial drug ever carried out in sub-Saharan Africa. The study is designed to monitor the efficacy and safety of ASAQ for the treatment of malaria. Since ASAQ is widely distributed, it is important to monitor the drug's safety and ensure its proper use. Thanks to MMV's support, 15,000 patients will be monitored over a two-year period.



▶ FOCUS

An ambitious drug-monitoring program in Africa

PATIENT 21

THE FIGHT AGAINST COUNTERFEIT DRUGS: A PUBLIC HEALTH CHALLENGE

OUR COMMITMENTS

Because the sale of counterfeit products over the Internet is a growing phenomenon, in 2009, sanofi-aventis increased its approach to fight counterfeit drugs with a two-fold objective: increasing awareness and enhancing safety.

The issue of counterfeit drugs remains a serious concern for sanofi-aventis. We are actively involved in combating counterfeit medicines, yet we believe that this struggle cannot become an obstacle to the legitimate sale of generic drugs in the interest of patients. Nonetheless, the Group remains vigilant, because generic drugs may be counterfeited as well.

WHAT IS A COUNTERFEIT? MEDICINAL PRODUCT ?

OUR ACTIONS



- Strengthening collaboration with international organizations, customs and police authorities ▶
- Establishing systems to prevent counterfeit products ▶
- Preventing drug counterfeiting through training programs ▶

▶ COUNTERFEIT DRUGS AND ACCESS TO MEDICINES: THE GROUP'S POSITION

THE FIGHT AGAINST COUNTERFEIT DRUGS: A PUBLIC HEALTH CHALLENGE

OUR ACTIONS

Strengthening collaboration with international organizations, customs and police authorities

In 2009, convinced that public/private cooperation is essential to effectively fight counterfeit drugs, sanofi-aventis increased the Group's active participation in international and local organizations. Internationally, the Group collaborates closely with the WHO, the pharmaceutical industry – the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and the European Federation of Pharmaceutical Industries and Association (EFPIA) – and the Pharmaceutical Security Institute (PSI). At the local level, the Group is very active in France with the CNAC (French National Anti-Counterfeit Committee) and LEEM (the French Pharmaceutical Companies Association); with the Quality Brands Protection Committee (QBPC) in China and the Pharmaceutical Research and Manufacturers of America (PhRMA) in the United States. Concurrently, it cooperates in joint operations with INTERPOL (International Criminal Police Organization), customs and police authorities to dismantle counterfeiting networks.

Establishing systems to prevent counterfeit products

In addition to safety labels on sensitive products, sanofi-aventis is working on high-tech solutions to make product traceability more reliable. The Group actively supports the European **Data Matrix** project based on a bar code system that makes it possible to ensure a medical product has not been falsified, from the time of manufacture up to the moment it is given to the patient. In 2009, sanofi-aventis took part in a pilot test in Sweden, where the preliminary findings were very positive. The objective is for all European countries to adopt this system, which is recommended by the EFPIA.

Preventing counterfeit drugs through training programs

Sanofi-aventis pursues an active training policy targeting employees as well as healthcare professionals and authorities. In 2009, in accordance with this policy, close to 1,000 police officers, customs officials and public health agents received training in 17 countries in Africa, Asia, Europe and the Middle East. Other milestones in 2009 included the Group's participation in a convention drafted by the Council of Europe to make the counterfeiting of medical products a criminal offense. In addition, at the end of 2009, sanofi-aventis signed the **Internet Charter to fight counterfeit drugs** in France.

▶ **SANOFI-AVENTIS, A PARTNER
IN THE DISTRIBUTION
OF QUALITY MEDICINES**
The Cotonou Declaration

BETWEEN 2008 AND 2009, THERE WAS A

70%

INCREASE IN THE NUMBER OF ARRESTS IN
CONNECTION WITH COUNTERFEIT COPIES
OF SANOFI-AVENTIS PRODUCTS

IN 2009,

1,685

PEOPLE RECEIVED TRAINING IN COMBATING
COUNTERFEIT DRUGS, INCLUDING 985 OUTSIDE
THE GROUP

ETHICS 21

Ethical
business conduct

▶ 29 COUNTRIES
IN THE RESPONSIBLE
PURCHASING
PROGRAM

Ethics
in research

▶ FOCUS
India

Respecting the rules of ethics: a major commitment

Respecting the rules of ethics in relation to Group employees, customers, suppliers and other stakeholders is one of the pillars of the sanofi-aventis CSR approach. The Group has chosen to define its commitments clearly and state them formally in a set of codes and charters that represent specific guidelines for both employees and partners. These commitments ensure the transparency of the Group's positions.

ETHICS 21

Sanofi-aventis is committed to acting in an ethical and responsible manner at every level of the Group's business activity: R&D, manufacturing, sales and marketing. Respecting human rights applying corporate governance rules and fighting corruption are fundamentals of the Group's business conduct. Additional fundamentals include compliance with good promotional practices and forging legitimate ties based on trust with all our stakeholders, specifically suppliers and sub-contractors.

Ethical business conduct

OUR COMMITMENTS

Ethical compliance is a very important issue for sanofi-aventis, which has developed codes and charters to provide the framework for its business activity. Moreover, the Group has implemented the necessary tools to monitor how this commitment is upheld with respect to both employees and stakeholders.

ENSURING RESPECT FOR **HUMAN RIGHTS**

APPLYING **GOOD CORPORATE GOVERNANCE RULES**

FIGHTING **CORRUPTION**

IMPLEMENTING A **RESPONSIBLE MARKETING POLICY**

PROMOTING CSR AMONG OUR **SUPPLIERS AND SUB-CONTRACTORS**

ETHICS 21

When it comes to human rights, sanofi-aventis must address the same issues facing all businesses, such as respect for working conditions and environmental protection. In addition, it must address issues that are specific to the pharmaceutical industry, such as exercising the right to health. The Group's policy is manifested in its actions and commitments, which take into account stakeholders' expectations and interactions. These commitments are based on compliance with various **guidelines**. The Code of Ethics and other codes, principles and charters adopted by sanofi-aventis are the clear expression of the Group's resolve to meet a two-fold objective: compliance with international standards and the development of monitoring tools and mechanisms that are necessary for stakeholder interaction.

ENSURING RESPECT FOR HUMAN RIGHTS

OUR ACTIONS

Identifying and responding to the challenges facing the Group

The principles set forth in universal human rights treaties apply to people and organizations, and consequently, to businesses. For each of the Group's various stakeholders (employees, patients, healthcare professionals, investors, suppliers, NGOs and local communities), sanofi-aventis has determined the relevant area of human rights as well as the codes and policies that exist in-house.

▶ HUMAN RIGHTS CONCERN ALL STAKEHOLDERS

Implementing monitoring and auditing procedures

The sanofi-aventis commitment to human rights is expressed through adherence to the Code of Ethics and other codes, principles and charters currently in effect within the Group. The Ethics Committee ensures that the integrity principles detailed in the Code of Ethics are applied throughout the entire Group. In addition, sanofi-aventis has implemented monitoring and auditing mechanisms in order to verify the actual application of its policies on this topic. To enhance these measures, in 2009 the Group adopted an assessment tool on a trial basis. **"Quick Check"**, developed by the Danish Institute for Human Rights, is an evaluation tool used to identify human rights risks in company operations.

Raising awareness and training employees about human rights

*In 2009, sanofi-aventis participated in the design and test phase of a new training tool for managers of various companies that are members of edH, entreprises pour les droits de l'Homme (Businesses for Human Rights).** The goal for 2010 is to gradually implement this tool.

▶ FOCUS
Businesses for Human Rights (edH)

* The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).

Good governance is the foundation upon which the Group's ethical conduct is built. It is a priority objective for sanofi-aventis and an on-going approach based on a specially adapted organization that relies on concrete and specific guidelines.

APPLYING GOOD CORPORATE GOVERNANCE RULES

OUR ACTIONS (part one)

Complying with the highest standards of good governance

Practices at sanofi-aventis comply with the recommendations contained in the NRE (*Nouvelles régulations économiques*) and in the AFEP-MEDEF *Code de gouvernement d'entreprise* (Corporate Governance Code). The Group has organized its internal control system through the distribution of Group codes and charters; their degree of implementation is monitored on a regular basis through audits and self-assessments.

Modifying the Directors' Code of the Board of Directors

The Directors' Code establishes the responsibilities of the Directors, the composition, duties and working procedures of the Board and its Committees, and the roles and powers of the Chairman and the Chief Executive Officer.

In late 2009, the Directors' Code was updated, in particular to take into account the recommendations of the AFEP-MEDEF Corporate Governance Code.

Overseeing ethical conduct: the Ethics Committee

In addition to specialized committees of the Board of Directors, in 2005 sanofi-aventis created an Ethics Committee. Comprised of the members of the Management Committee, its primary role is to monitor the application of the values and integrity principles described in the Code of Ethics. In late 2009, the Senior Vice President Corporate Social Responsibility was named the Chairman of the Ethics Committee.*

▶ GOOD GOVERNANCE PRACTICES

▶ For more information, see website **sanofi-aventis**
2009 *Document de Référence*:
section 1.2 *Gouvernement d'entreprise*
section 3.2 *Rapport du Président du Conseil d'administration*

2009 Form 20-F
Part II, Item 16G, Part II, Item 15

▶ For more information, see website **sanofi-aventis**
2009 *Document de Référence*:
section 1.2.2.B *Conseil d'administration*

2009 Form 20-F
Part I, Item 6

▶ CODE OF ETHICS

* The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).

APPLYING GOOD CORPORATE GOVERNANCE RULES

OUR ACTIONS (part two)

Ensuring the protection of personal data

Sanofi-aventis complies with legislation –including the European Directive of October 24, 1995, and local regulations in the countries where the Group operates– that sets up the framework for personal data processing related to individuals and the protection of their right to privacy.

The Group's commitment is also expressed through the implementation of standards and initiatives in this area, such as:

- the sanofi-aventis Code of Ethics;
- the Group's Personal Data Protection Charter;
- the implementation of Binding Corporate Rules (BCR) concerning the transfer of certain types of information within the Group, between affiliates within the European Economic Area (EEA) and those located outside the EEA. The BCR represent a set of rules developed by the Group and validated by the CNIL (the French national data protection authority) in France.

Moreover, sanofi-aventis has developed training modules about personal data and BCR. They are available via the Group's Intranet so that each employee can learn more about these issues.

Optimizing the internal control system

Senior Management expresses its clear commitment to maintain and improve a reliable and effective internal control system, built on tailored organizational structures, well-defined responsibilities and demonstrated competencies. The overall objective is to promote management's transparency, the principle characteristic of good governance. **A Code of Internal Control Principles** is distributed to Group affiliate managers.

▶ For more information, see website **sanofi-aventis** 2009 *Document de Référence*: Section 2.C.C

ETHICS 21

The economic, social and political cost of corruption is very high and its impact on essential sectors, such as the healthcare sector, is substantial. As economic players, all companies are faced with this issue. In light of this situation, sanofi-aventis has for several years been strengthening its approach to fighting corruption in all countries where the Group operates and across all its spheres of influence.

▶ **THE PHARMACEUTICAL INDUSTRY, A SENSITIVE SECTOR**

FIGHTING CORRUPTION

OUR ACTIONS

Fighting corruption: a priority in our Code of Ethics

Fighting corruption is one of the central themes in the sanofi-aventis Code of Ethics. The Code explicitly bans direct and indirect corruption and limits corporate gifts including promotional items, samples and cultural gifts of a lesser value, in compliance with local regulations. Outside contractors receive a separate Suppliers Code of Conduct with which they must comply, as well as an Ethics Charter for Purchasing. This charter has been distributed to Group buyers, who also receive specific training.

▶ **SOLID GUIDELINES IN THE FIGHT AGAINST CORRUPTION**

Raising awareness about the fight against fraud and corruption

*In order to increase awareness among Group directors, managers and employees, sanofi-aventis communicates information about fraud detection and prevention to all affiliate general managers worldwide.** The Chief Executive Officer and Executive Vice President Finance of sanofi-aventis evaluate the adequacy and effectiveness of the Group's control over published financial information and fraud.

*Local chief financial officers sign an attestation letter twice a year to demonstrate their commitment to the process and to report any fraudulent cases that occurred during that time period. There is no minimum value included in the definition of fraud and appropriate sanctions are levied in all cases.**



C. Viehbacher, 2009 Compliance Campaign

In-house tools help build awareness about corruption

Creating an effective alert system

The Group has an alert system designed to facilitate reporting of any failures to respect Group codes in terms of accounting and financial standards, corruption and internal control. In 2009, the total number of calls received on the alert hotlines from sanofi-aventis affiliates worldwide reached 900. Of these calls, 240 met the definition of a potential violation and were investigated; 35% of these alerts led to disciplinary sanctions.

** The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).*

ETHICS 21

IMPLEMENTING A RESPONSIBLE MARKETING POLICY

Sanofi-aventis is obligated to responsibly utilize the rules of good promotional practices when communicating information about our medicines and vaccines. Our stakeholders expect a clear commitment to greater transparency, ethics and standards. Regardless of the promotional materials used, the Group must provide all necessary information to prescribing physicians about the proper use of a medicine so they can make an informed decision about the product's risk/benefit ratio. Similarly, the patient must receive all useful information to ensure the rational use of a non-prescription drug.

OUR ACTIONS



- Review and validation of the practices and presentations of medical sales representatives ▶
- Ensuring compliance of all promotional materials ▶
- Organizing and participating in congresses and scientific events ▶

▶ GUIDELINES AND PROCEDURES FOR PROMOTIONAL PRACTICES

▶ STAKEHOLDERS' EXPECTATIONS

IMPLEMENTING A RESPONSIBLE MARKETING POLICY

OUR ACTIONS

Review and validation of the practices and presentations of medical sales representatives

The Group is responsible for ensuring that the message conveyed by medical sales representatives is fair, balanced and accurate. The information provided by representatives must be fair and ethical, and it must comply with regulatory requirements and in-house conduct standards concerning the promotion of medicines. Practices during pharmaceutical sales visits and the approach taken by medical sales representatives are monitored and evaluated on a regular basis.

Ensuring compliance of all promotional materials

*The sanofi-aventis Global Medical Affairs Department is in charge of monitoring promotional materials developed within the Group** in order to ensure that they all comply with **international standards as well as Group procedures**. Sanofi-aventis has developed various **websites** designed for different stakeholder groups to communicate about the Group's activities and establish platforms for information exchange. For all these tools, the Group carries out **audits** to ensure full application and compliance with in-house procedures concerning promotional materials.

Organizing and participating in congresses and scientific events

Sanofi-aventis organizes a number of congresses and scientific events. These encounters provide a forum for exchange with the scientific community about new therapeutic developments. They also offer an excellent opportunity for sanofi-aventis to communicate about new scientific data and the Group's products.

The Group applies all the **international rules and regulations** governing these events and implements controls to ensure compliance with these rules.

Global Medical Affairs examines all promotional documents created for seminars and medical events. In addition, Group employees receive training about the rules to follow when organizing all types of scientific events.

▶ IN FRANCE,

2,043

MEDICAL SALES REPRESENTATIVES' PRESENTATIONS WERE EVALUATED IN 2009



Monitoring promotional materials in 2009



Different kinds of scientific events

* The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).

ETHICS 21

PROMOTING CSR AMONG OUR SUPPLIERS AND SUB-CONTRACTORS

Each year, sanofi-aventis purchases goods and services for a total of over 10 billion euros. Consequently, the ethical, social and environmental perspectives of its suppliers are of utmost importance to the Group. With suppliers that are selected to work with sanofi-aventis, the Group is committed to sharing both the fundamental principles of the United Nations' Global Compact and the Group's eco-responsible values. The overall objective is first to ensure that suppliers adhere to good social and environmental practices and second, to incorporate sustainability as a factor for the products and services purchased by the Group.

OUR ACTIONS



- Continuing the training and awareness program for buyers ▶
- Improving awareness of the Group's CSR approach and evaluating suppliers ▶
- Choosing goods and services that go further to respect the environment ▶

▶ EVALUATION OF PURCHASING CATEGORIES INVOLVING RISK

PROMOTING CSR AMONG OUR SUPPLIERS AND SUB-CONTRACTORS

OUR ACTIONS

Continuing the training and awareness program for buyers

The sanofi-aventis Responsible Purchasing Program is designed to improve awareness among Group suppliers and monitor their compliance with good social and environmental practices. The program is based on training sessions specifically targeting buyers to ensure that they have a sound understanding of international agreements, standards and principles. Today more than 80% of Group buyers have received this training. In addition, all regional Purchasing Department conferences routinely include Responsible Purchasing on their agendas.

Several countries became new members of the Responsible Purchasing Program in 2009, including Australia, Brazil, China, Greece, Mexico and Poland. Today 48 Purchasing entities in 29 countries apply the program's principles.

▶ 29

COUNTRIES IMPLEMENTED THE RESPONSIBLE PURCHASING PROGRAM

Improving awareness of the Group's CSR approach and evaluating suppliers

*Following a decision to associate a risk level with each purchasing category, the Group developed a risk scale and incorporated it into the global supplier database. Two criteria are assessed: the risk of social and environmental controversy, and the risk that such a controversy could harm sanofi-aventis' reputation. In addition to this risk scale, Group buyers may ask suppliers to undergo an evaluation, which consists of a questionnaire and an interview.** In certain countries, such as India and China, where the risks are considered to be more significant, the Group routinely evaluates all chemical product suppliers.

▶ 1,728

SUPPLIERS EVALUATED OR BEING EVALUATED

Choosing goods and services that go further to respect the environment

Sanofi-aventis is committed to respecting the environment on a day-to-day basis through its purchasing policy, with the goal of reducing the Group's carbon footprint. Today it has adopted the use of a certified electronic product registration system (e.g., the Electronic Product Environmental Assessment Tool, or EPEAT) to ensure that the electronic products we purchase adhere to environmental standards (energy consumption reduction).

In addition, the Group promotes fair trade by purchasing work garments that are manufactured with fair trade cotton. Lastly, when purchasing office equipment and supplies, it seeks products that take into account sustainability, (i.e., products that can be recycled or are made of recyclable or environmentally-certified materials).

▶ FOCUS

Promoting environmentally-friendly materials

** The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).*

ETHICS 21

Scientific and medical research is an essential part of preventing and combating disease, and it demands full transparency toward stakeholders and involves far-reaching ethical considerations. For this reason, research occupies a key position in the sanofi-aventis CSR policy.

OVER

31,000

PATIENTS INCLUDED IN CLINICAL TRIALS IN

75 COUNTRIES

Ethics in research

OUR COMMITMENTS

The Group is committed to contributing to the development of new medical approaches with complete respect for ethics rules and regulatory frameworks. It is also ready to adjust management structures to meet these new challenges.

ENSURING PATIENT SAFETY:
ETHICS AND TRANSPARENCY OF **HUMAN CLINICAL TRIALS**

PLACING **BIOETHICS** AT THE CENTER OF THE GROUP'S PRIORITIES

ETHICS 21

ENSURING PATIENT SAFETY: ETHICS AND TRANSPARENCY OF HUMAN CLINICAL TRIALS

Before new treatments can be offered to patients, it is essential to be certain they are both safe and effective. The Group organizes numerous clinical trials and observational studies throughout the world in order to study the efficacy and tolerance of products in development. Additionally, these trials provide new data about products that are already on the market. Above all, the Group is committed to ensuring patients' safety in full compliance with **ethics rules and regulatory requirements** concerning good clinical and epidemiological practices. This also requires transparent and proactive communications about how trials are conducted as well as their results.

OUR ACTIONS



- Respecting the ethics rules that apply to all human clinical trials ▶
- Ensuring information transparency about clinical trials ▶
- Conducting clinical trials in developing countries ▶

ENSURING PATIENT SAFETY: ETHICS AND TRANSPARENCY OF HUMAN CLINICAL TRIALS

OUR ACTIONS

Respecting the ethics rules that apply to all human clinical trials

*Before a clinical trial or an observational study may begin, it is routinely subject to review by a multidisciplinary approval board. For the most sensitive types of studies (R&D studies for marketing registration and pivotal local and global studies), this review is followed by a second evaluation under the responsibility of a senior committee. The goal is to ensure the application of ethics rules concerning clinical trial research, the scientific relevance of the study, patients' safety, and compliance with Good Clinical Practices. Together these factors determine the ethical status of studies.** Information about the studies is then submitted to the health authorities and to independent ethics committees in accordance with local and international regulations. Moreover, sanofi-aventis systematically requires the patients' **free and informed consent** regardless of the project type – clinical trial or observational study.

Ensuring information transparency about clinical trials

The sanofi-aventis Group is committed to transparency about the clinical trials it conducts. The public has access to information about ongoing clinical trials as well as the results of completed clinical trials. This information may be found on the clinical trials registry at www.clinicaltrials.gov as well as on the results database at www.clinicalstudyresults.org.

Conducting clinical trials in developing countries

Trials conducted by sanofi-aventis in developing countries are subject to the same ethics rules as any other clinical trial carried out by the Group. The Group conducts clinical trials in countries with ethics committees. Since 2007, sanofi-aventis has voluntarily submitted its malaria clinical trial protocols to a **French independent review board** (CPP, *Comité de Protection des Personnes*). In an advisory capacity, this committee reviews projects to be carried out in developing countries.

WEB ► *Clinical trials registry*
www.clinicaltrials.gov

WEB ► *Results database*
www.clinicalstudyresults.org



FOCUS
India

* The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).

ETHICS 21

Because researchers today are able to work directly with living organisms, including human beings, the Group is committed to contributing solutions to the development of new medical approaches. It relies on expertise found both in-house and external to the Company to address the bioethics issues that concern sanofi-aventis.

PLACING **BIOETHICS** AT THE CENTER OF THE GROUP'S PRIORITIES

OUR ACTIONS

Overseeing the management of challenges relating to bioethics

Sanofi-aventis must be certain that all avenues of innovation and R&D respect the bioethics rules defined by the Group. To ensure that this mission is fulfilled, in 2009 the Group created the position of Chief Medical Officer (CMO). One of the CMO's responsibilities is to supervise all these factors in a cross-functional approach that facilitates information exchange and makes it possible to improve monitoring procedures.

Supporting the efforts of the Bioethics Committee

The Chief Medical Officer is creating a structured framework to promote discussion and actions about bioethical issues by establishing a special governance body: the Bioethics Committee, which is a sub-committee of the Group's Ethics Committee. Founded in 2009, the Committee will become fully operational in 2010. Its primary objective will be to draft a bioethics charter that will define the Group's commitments and restrictions in this field, and will specify the investigational areas pursued by sanofi-aventis.

PEOPLE 21



Developing talent: a key asset for sanofi-aventis

The implementation of sanofi-aventis' transformation program has given rise to major changes within the Group. Sanofi-aventis is addressing these changes while being mindful of the Group's values and the commitments it has made to its employees.

Throughout 2009, the sanofi-aventis Group took on numerous challenges while focusing its efforts on supporting the transformation of its functions, developing employee talent and ensuring employee health and safety while continuing to prevent all forms of discrimination.

PEOPLE 21

SUCCESSFULLY SUPPORTING CHANGE

OUR COMMITMENTS

Sanofi-aventis is fully committed to supporting its employees during the Group's functional and organizational changes. In each country, the Group implements the best means for providing local support in order to make this transformation successful.

One of the objectives of sanofi-aventis' transformation program is to provide the Group with cutting-edge innovative R&D capabilities and to diversify its activities through acquisitions. As such, it is important to adapt the Group's organizational structure to keep pace with the changing socio-economic climate and to address new challenges in the healthcare sector.



Sanofi-aventis Vietnam recognized

OUR ACTIONS



- Assisting employees during the Group's transformation ▶
- Strengthening and integrating teams in areas with high growth potential ▶

SUCCESSFULLY SUPPORTING CHANGE

OUR ACTIONS

Assisting employees during the Group's transformation

Some of the changes within sanofi-aventis involve converting certain chemical industrial sites into biotechnology sites, particularly in France and Germany. In order to ensure that its workforce remains employable, the Group provides training in new skills, thus creating centers of excellence for these new functions.

The Group is vigilant about maintaining internal and external mobility. The goal is to implement a system that enables each employee to find a solution that is right for him or her. In France, during 2009, the Group created a special 13 million euros training fund to help employees acquire new skills. Also in France, a Group-financed plan for voluntary departures (based on anticipated work departures) was implemented. Finally, sanofi-aventis has a dedicated entrepreneurial unit that is tasked with assisting employees who would like to start a business or acquire an existing business.

While the Group has scaled down its operations and combined some of its sites, it is committed to remaining an economic and social player in France and maintaining strong business activities within the country. The Group's affiliate **SOPRAN** plays an active role in the economic framework in the regions where the Group operates. SOPRAN organizes initiatives to promote regional revitalization and assists with job creation in small and medium-size firms.

Strengthening and integrating teams in areas with high growth potential

Over 8,900 people joined the Group from the 11 entities acquired in 2009, and most of these new employees work in manufacturing and sales. These **11 entities** are divided geographically between Europe (six companies/6,100 people), Latin America (three companies/2,000 people), India (one company/800 people) and the United States (one company).

These entities help strengthen sanofi-aventis' expertise and presence in certain areas of the world where access to medicines represents a major healthcare challenge for local communities.

59 businesses were created in 2009

OVER

8,900

NEW EMPLOYEES JOINED THE GROUP WITH THE ACQUISITION OF 11 COMPANIES IN 2009

In an ever-changing and highly-competitive environment, sanofi-aventis understands the importance of offering its managers and employees the means to acquire and develop the skills needed to ensure the Group's long-term success.

DEVELOPING TALENT AND CAREERS

OUR COMMITMENTS

Sanofi-aventis strives to develop the talent of its employees to offer solid support for the transformation of its business model. The Group has also implemented a career development policy.

OUR ACTIONS



- Encouraging professional development for our managers ▶
- Facilitating access to self-learning ▶
- Strengthening ties with schools ▶

DEVELOPING TALENT AND CAREERS

OUR ACTIONS

Encouraging professional development for our managers

In 2009, 472 Group managers selected based on their potential received training in one of the five programs developed by sanofi-aventis: **Discover, Explore, Evolve, Pilote and Perspectives**. All of the programs are international in scope, including the Pilot program, which was designed for French-speaking countries and further enriches a broad range of training options in different countries and functions. They have been developed for different types of managers, both those who are new to the job and those who have significant experience within the Group.

These programs allow managers to acquire the skills they need to support the transformation of sanofi-aventis: understanding the Group's challenges, capitalizing on the ability to take initiative, developing an international network and leading a team.

Facilitating access to self-learning

In order to make training available to as many employees as possible, sanofi-aventis gradually introduced a shared "Le@rn" e-learning platform in 2009 throughout all Group entities for its e-learning modules. More than 13,000 e-learning modules are available in ten languages. They focus primarily on training related to the Group's activities. By the end of 2009, 34,000 employees had access to "Le@rn" in 20 countries.

The Group also offers electronic training sessions via the Group's Intranet, such as a training module on combating corruption.

Strengthening ties with schools

By developing long-term relationships and partnerships with **schools and universities**, sanofi-aventis enables students to discover the wide range of professions within the Group and tap into the expertise of its teams. Building relationships with these young people offers significant advantages, as one day they may become employees and help the Group develop its business activities. In 2009, the Group had over **1,700 interns** from a wide variety of schools and backgrounds, **405 young people in work-study programs** in France, and **more than 150 recent graduates** in the International Corporate Volunteer program, known as VIE.

IN FRANCE, **87%** OF EMPLOYEES BENEFITED FROM TRAINING INITIATIVES

▶ For more information, see website **sanofi-aventis** People development

13,000 E-LEARNING MODULES ARE AVAILABLE



▶ **FOCUS** Work-study programs: discovering the professional world

PEOPLE 21

The Group focuses on promoting equal opportunity and reasonable working conditions for all, regardless of gender, ethnic origin, sexual orientation, religion, age or disability. Managing diversity requires taking into account individual differences that are unseen as well as those that can be observed. Promoting diversity is an integral component of the Group's Code of Ethics and its Social Charter.


For more information, see website [sanofi-aventis Diversity](#)

MAKING A COMMITMENT TO DIVERSITY

OUR COMMITMENTS

As a multinational company that strives to respect different cultures, sanofi-aventis depends on the diversity and wide-ranging talents of its employees to make the Group more innovative, effective and competitive.

OUR ACTIONS



- Promoting employee awareness: World Diversity Tour ▶
- Preventing all forms of discrimination ▶
- Developing gender equity at all levels of the organization ▶
- Expanding recruitment and continued employment of people with disabilities ▶

▶ ONE COMMITMENT – THREE PRINCIPLES

MAKING A COMMITMENT TO DIVERSITY

OUR ACTIONS (part one)

Promoting employee awareness: World Diversity Tour

Launched at the end of 2009, the World Diversity Tour is an awareness-building and informational program designed to highlight the Group's commitments to diversity, establish local initiatives and communicate about these initiatives. This project, which is overseen by Senior Management, reflects the Group's commitment to these subjects. The Group relies on Diversity Representatives in its countries of operation to drive change and ensure that this policy is implemented locally. The initiatives carried out are showcased on the Group's Intranet.*

Preventing all forms of discrimination

In order to strengthen the spirit of non-discrimination among all employees, training modules are developed to provide information on this topic. In France, the Group has undertaken two types of programs:

- one-day programs to raise awareness about diversity and the different reasons for discrimination. Over three years, more than 136 Human Resources managers have been trained.
- a half-day program for managers at industrial sites. Training was carried out at seven sites, with over 130 people trained in 2009.



** The information in italics identified by an asterisk was reviewed by the Statutory Auditors, who expressed an assurance specifically concerning these data. Their assurance statement, describing the work they performed as well as their comments and conclusions, appears in the sanofi-aventis 2009 CSR Report and on the Group's 2009 CSR website (section: Statutory Auditors' Review Report).*

MAKING A COMMITMENT TO DIVERSITY

OUR ACTIONS (part two)

Developing gender equity at all levels of the organization

Eager to make the most of employee talent, sanofi-aventis has made gender equity one of its priorities. In 2009, 46.6% of the Group's employees were women. Since 2008, the proportion of women executives has increased by 0.6%, reaching 45.1%.

At the end of 2009, five women were members of the Group Management Committee, which is made up of 23 members. Of these five women, two were members of the Executive Committee, which is made up of 9 members. There was one woman on the Board of Directors. Throughout the Group, **14%** of women hold key positions with operational responsibility.

46.6%
OF THE GROUP'S EMPLOYEES ARE WOMEN


Expanding recruitment and continued employment of people with disabilities

The Group's commitment is based on retaining employees who have become disabled, integrating disabled employees, as well as encouraging sub-contracting activities to specialized centers and offering training and raising awareness for employees about disability in the workplace.

At the end of 2009, the Group had 1,772 employees with disabilities in over 40 countries (compared with 1,631 in 2008). Over 50% of these employees work in industrial operations.

Many countries, such as Morocco, Japan, Egypt and **France**, have introduced new initiatives in 2009 in line with the Group's commitments to disability.

SINCE 2008, THERE HAS BEEN AN **8%** INCREASE IN THE NUMBER OF PEOPLE WITH DISABILITIES EMPLOYED BY THE GROUP WORLDWIDE



VIDEO
Xavier: The Art of Communication

PEOPLE 21

The Group seeks to limit the number of occupational accidents and safeguard the health of employees. Regardless of the nature and type of collaboration (involving Group employees, temporary employees or staff from external service providers), sanofi-aventis has adopted a policy to assess and control risks. The Group has put in place **monitoring systems** for occupational health and safety that are tailored to each of its business activities.

ENSURING OCCUPATIONAL HEALTH AND SAFETY

OUR COMMITMENTS

Sanofi-aventis' objective is to continually assess potential occupational injury and health risks to employees in the workplace. This requires ensuring prevention and protection by offering employees information and training so that they can play an active role in their own health and safety.

OUR ACTIONS



- Protecting the health and improving the well-being of employees ▶
- Increasing awareness of motor vehicle safety ▶
- Developing an Health Safety Environment (HSE) culture ▶
- Sharing experiences ▶

ENSURING OCCUPATIONAL HEALTH AND SAFETY

OUR ACTIONS

Protecting the health and improving the well-being of employees

Sanofi-aventis focuses on identifying and assessing risks, ensuring monitoring, promoting feedback about experiences and developing a culture of prevention. Whether in terms of managing occupational illnesses or preventing psychosocial risks, the Group strives to ensure that all its employees have a satisfactory working environment.

Increasing awareness about motor vehicle safety


Due to the disturbing number of motor vehicle accidents involving medical sales representatives, the Group instituted a **long-term program** to reverse this trend in 2006. This approach was based on decisive involvement from management, a dedicated communication campaign and adapted training. Since 2006, the motor vehicle safety campaign has made it possible to achieve a nearly 30% decrease in the occupational lost-time accident **frequency rate** involving motor vehicles. Despite these encouraging results, tragically there were three fatal motor vehicle accidents in the Group in 2009. New initiatives will be implemented in 2010.

Developing an Health Safety Environment (HSE) culture

Offering HSE culture training to managers provides them with know-how and enables them to properly assess the risks that employees are exposed to in their work environment. Over 900 managers received training in 2009 (representing more than 12,000 hours of training). The Group has decided to continue implementing HSE culture training in-house and expand this training to newly-acquired entities. HSE managers at Zentiva sites, which were acquired in 2009, received five days of training.

Sharing experiences

The Group's strength lies in the diversity of its employees and the experiences that they face. Sanofi-aventis has implemented **“knowledge sharing and feedback” days**, in France and other countries, among site managers.




FOCUS

Occupational health and well-being: 2009 data

For more information, see website **sanofi-aventis** Occupational health and safety

PLANET 21



Preserving the planet: a vital responsibility for the Group

Sanofi-aventis continuously seeks ways to limit the environmental impact of its business activities, protect public health and combat climate change. The Group's concern for environmental performance guides its day-to-day activities. The Group has implemented a dedicated management system to ensure compliance with national laws, international protocols and the highest environmental standards.

PLANET 21

HSE MANAGEMENT SYSTEM

OUR COMMITMENTS

Faced with constant changes in its product portfolio, variations in the number of units to manufacture as well as changes in the number of production sites, sanofi-aventis puts systems in place that help limit its environmental impact and enable the Group to be environmentally responsible. The key challenges involve reducing waste, managing natural resource consumption, protecting soil and surface water and limiting greenhouse gas emissions.

The key areas of the Group's environmental management system involve developing and utilizing safe industrial processes as well as limiting environmental impact.

This system is part of an Health, Safety and Environment (HSE) management system that also aims to protect the health and safety of Group employees. The **HSE management system** is continuously being adapted to improve performance and manage HSE risks.

OUR ACTIONS



- Solidly integrating the HSE policy within the Group ▶
- Ensuring proper application of regulations and internal procedures ▶
- Improving feedback about experiences ▶
- Expanding ISO environmental certification to other Group production facilities ▶

HSE MANAGEMENT SYSTEM

OUR ACTIONS (part one)

Solidly integrating the HSE policy within the Group

Sanofi-aventis has implemented an HSE management system that covers all levels of its operations and promotes the continuous improvement of the Group's HSE performance. It is based on an integrated policy with eight guiding principles and **77 requirements**. Over 500 people worldwide are dedicated to these HSE processes, and their work relies on a structured document hierarchy as well as various **tools** designed to correct any failures to comply with the policy and minimize non-compliance. HSE performance is measured using reporting tools, self-inspections and audits. Regular department reviews are carried out to monitor current programs, assess progress and adapt the Group's HSE strategy.

▶ THE EIGHT GUIDING PRINCIPLES OF THE SANOFI-AVENTIS HSE POLICY

Ensuring proper application of regulations and internal procedures

Sanofi-aventis must ensure that rules and procedures are properly applied. The Group uses **audits** to ensure compliance with all current procedures and regulations. These audits are part of a progress-based approach for all of the organizations involved.

They are divided into three categories: general audits aimed at ensuring compliance with Group rules; specialized audits that target a specific area (i.e., "Nitrogen" or "Outside service providers") and technical visits focusing on compliance with insurance-based risks, which are carried out with insurance adjusters.

HSE MANAGEMENT SYSTEM

OUR ACTIONS (part two)

Improving feedback about experiences

Continuous HSE performance improvement is based on four key areas: document hierarchy; developing HSE expertise and an HSE culture; audits and systematic monitoring of corrective and preventive actions; and feedback about HSE events.

Analyzing the causes of injuries and incidents and taking steps to find solutions are crucial to progress. An expert from the central HSE team is tasked with finding possible recurring causes of various types of events and is also responsible for suggesting preventive actions. This information is shared with appropriate managers, both within and outside the Group, so that they can utilize it to help prevent such events from being repeated.

OVER
500
PEOPLE DEDICATED
TO HSE PROCESSES WORLDWIDE

Expanding ISO environmental certification to other Group production facilities

Striving to highlight its achievements in environmental management and have them recognized beyond the Group, sanofi-aventis places special emphasis on encouraging the ISO certification process of its production sites.

ISO 14001 focuses on the continuous improvement of environmental performance by controlling impacts related to the Company's activities.

Today, out of the Group's 82 industrial sites worldwide, 39 hold ISO 14001 certification. The Hangzhou site in China and the Holmes Chapel site in the United Kingdom were certified in 2009. Three R&D sites and several administrative sites have also received certification.

39 ISO 14001
CERTIFIED INDUSTRIAL
SITES AT THE END OF 2009

PLANET 21

Manufacturing a drug or a vaccine may potentially have an impact on the local environment. Sanofi-aventis affirms its commitment to protecting the planet and seeks to limit its impact in terms of natural resource utilization, air quality and waste production.

LOCAL ENVIRONMENTAL FOOTPRINT

OUR COMMITMENTS

Through its initiatives to limit water consumption and wastewater discharge, preserve air quality, maintain a responsible waste management policy and remediate contaminated soil, the HSE Department raises awareness at all sites about the importance of adhering to the Group's environmental approach.

OUR ACTIONS



- Reducing water consumption ▶
- Limiting industrial wastewater discharge ▶
- Preserving air quality ▶
- Sorting and recycling waste ▶
- Remediating contaminated soil ▶

LOCAL ENVIRONMENTAL FOOTPRINT


OUR ACTIONS (part one)

Reducing water consumption


Sanofi-aventis knows that water is a precious natural resource: the WHO estimates that approximately one billion people in the world do not have access to potable water. Water utilized during the various stages of the industrial processes (i.e., fermentation and vaccine manufacturing) and for cooling systems during manufacturing account for most of the Group's water consumption. Sanofi-aventis has modernized its water management processes, particularly for closed-loop cooling facilities. Specific initiatives have also been initiated to improve water utilization. Water consumption decreased by nearly 2% in 2009.

Limiting industrial wastewater discharge

One of the 77 HSE requirements addresses the treatment of industrial effluents from production sites. Industrial effluent waste is either treated in sanofi-aventis' waste treatment facilities or at various local treatment plants, based on agreements made with operators. Thanks to successful efforts at all the plants, sanofi-aventis achieved an 8% reduction in chemical oxygen demand (COD), the primary environmental indicator of effluent quality. In 2009, the Group made significant strides to improve treatment system efficacy before discharge, thereby reducing nitrogen by 5%. However, due to a significant increase in production volumes for two biochemical sites that use fermentation in their processes, there was a 21% increase in total suspended solids.



Variation in water consumption



Variation in wastewater discharge


► For more information, see website **sanofi-aventis**
 2009 Document de Référence:
 Section 3.1.9 Données environnementales

LOCAL ENVIRONMENTAL FOOTPRINT

OUR ACTIONS (part two)

Preserving air quality


Local air quality is primarily affected by volatile organic compounds (VOCs), while nitrogen oxides (NOx) and sulfur oxides (SOx) impact air quality to a lesser degree. In 2009, sanofi-aventis took significant steps within its production sites to reduce VOC emissions by 5% and SOx emissions by 8%.



Emissions affecting air quality (excluding CO₂)

Sorting and recycling waste

Waste management and reduction are important objectives for sanofi-aventis. The Group systematically prefers waste conversion, either through recycling or waste to energy conversion. The increase in hazardous waste (+8%) is primarily due to an increase in production at two sites. In 2009, waste conversion was used to treat nearly 55% of the hazardous waste produced. There was also a similar increase in non-hazardous waste treatment: 68% was treated using either recycling or waste to energy conversion.



Waste management

Remediating contaminated soil

Sanofi-aventis adopts a responsible approach to managing the sites where the Group operates. Remediation costs amounted to 38 million euros in 2009. The Company applies a multi-year soil and sub-soil monitoring and evaluation program for the Group's properties, both for those that are currently and formerly owned and operated. Sanofi-aventis relies on detailed risk evaluations of soil and sub-soil contamination. These evaluations are carried out, when necessary, at the Group's sites or former sites. Remediation projects are launched either by local authorities or by the Group. Remediation is underway at 16 sanofi-aventis sites worldwide as well as several other sites that have been sold to third parties with environmental guarantees from the Group.

38 million euros

INVESTED IN REMEDIATING CONTAMINATED SOIL IN 2009

► For more information, see website **sanofi-aventis** 2009 *Document de Référence*: Section 3.3.2 *États financier consolidés annuels* 2009 Form 20-F Note D.18.3

PLANET 21

As an economic player in the healthcare sector, sanofi-aventis has adopted ambitious requirements and action plans to fight climate change. All of the initiatives taken, both within and outside the Group, meet specific environmental criteria designed to limit the Group's carbon footprint.

For more information, see website [sanofi-aventis Climate change](#)

THE STRUGGLE AGAINST CLIMATE CHANGE

OUR COMMITMENTS

Sanofi-aventis seeks to minimize greenhouse gas emissions and reduce energy consumption to limit the Group's carbon footprint. Sanofi-aventis is committed to reducing direct and indirect emissions by 15% between 2005 and 2013. By 2011, the Group has also established a goal to conduct a comprehensive evaluation of "other indirect" emissions for which we have no direct control. These actions are being carried out in conjunction with those already in place for transport and business travel.

OUR ACTIONS



- Pursuing improvement programs ▶
- Controlling and optimizing energy consumption ▶
- Pursuing greenhouse gas emission reduction programs ▶
- Reducing carbon dependence related to material and service purchases ▶
- Developing alternative solutions ▶
- Promoting "green" as well as virtual meetings ▶

THE STRUGGLE AGAINST CLIMATE CHANGE

OUR ACTIONS (part one)

Pursuing improvement programs

Reducing energy consumption helps deal with climate change and requires making the right investments at every site. **The many possibilities for improvement** are often easy to implement. For example, a practical guide was distributed to Group site managers providing eco-responsible management guidelines to help foster change in practices and behaviors.

In order to reward the best practices from sites within the Group, the annual Climate Change Awards were launched in 2007.




Climate Change Awards

Controlling and optimizing energy consumption

Even though the manufacturing activities of the pharmaceutical industry do not necessarily require a significant amount of energy consumption, the Group strives to control the amount of energy needed. In 2009, energy consumption increased by 3.7%. This can be explained by a significant increase in the volume of drugs and vaccines manufactured, as well as an increase in the use of cogeneration, which consumes more energy but generates less CO₂ emissions.

Overall the ratio of CO₂ emissions per unit produced has been reduced by 11% since 2005.




Energy consumption

Pursuing greenhouse gas emission reduction programs

Within the scope of the Kyoto Protocol, the Group has established **ambitious goals** to reduce greenhouse gas emissions from 2005 to 2013.

Six of the Group's European industrial sites are included in the EU greenhouse gas emission allowance trading scheme. Four other sites participate indirectly via their steam suppliers.



Greenhouse gas emissions

THE STRUGGLE AGAINST CLIMATE CHANGE

OUR ACTIONS (part two)

Reducing carbon dependence related to material and service purchases

Since 2007, sanofi-aventis has focused on qualifying and quantifying emissions that are generated as a result of **the Group's purchases**. Six internal entities representative of the Group activities assessed their carbon emissions in 2008 and 2009. This pilot strategy will be scaled up over 2010 and 2011 to obtain an overview of the third-party emissions generated by sanofi-aventis' activities. An action plan will be put in place to reduce the Group's dependence on fossil fuel sources and encourage service providers to take similar steps. The Statutory Auditors carried out a pre-audit to review the action plan methodology, the tools it uses and its scope. Preliminary findings show that the work undertaken is consistent with the action plan goals.

Developing alternative solutions

In practical terms, sanofi-aventis has implemented significant alternative solutions: thermal or photovoltaic solar energy production at certain sites, heat recovery at production plants, cogeneration at over ten sites, geothermal energy, vehicles with lower CO₂ emissions, less air transport and more ocean transport between major distribution platforms, less road transport and more waterway/rail transport, etc.

Promoting "green" as well as virtual meetings

How can sanofi-aventis maintain its presence at congresses and other events while being eco-responsible? The Group created a **green meeting taskforce**, whose first initiative was to draft a guide to support decision-making and improved practices. The guide includes a carbon calculator and a self-diagnostic tool for those organizing professional events.

Virtual meetings are also being used to allow more participants to be involved in conferences, discussions and informational meetings via computers available at their workstations or special videoconferencing rooms. A working group is assessing these new technologies. These initiatives allow participants to avoid traveling to event locations, thus significantly reducing travel-related CO₂ emissions.



Innovative alternative solutions

The Group's "green attitude"

PLANET 21

Trace levels of pharmaceuticals may be found in the environment primarily as a result of patient use. Due to the potential risks for human health and the environment, this issue is the focus of growing concern, and sanofi-aventis considers it a key part of the Group's commitment to CSR-in much the same way as eco-product design.

THE ENVIRONMENTAL FATE OF THE GROUP'S PRODUCTS

OUR COMMITMENTS

Going beyond compliance with regulatory requirements, the Group assesses the environmental impact of certain drugs already marketed by sanofi-aventis. Additionally, it conducts tests to assess the environmental risks resulting from patient utilization and helps contribute to scientific knowledge in this field. Another objective is to pursue programs that promote the eco-design of products and support local collection programs for unused medicines.

OUR ACTIONS



- Internally assessing the Group's products ▶



- Working in close collaboration with stakeholders ▶



- Promoting the eco-design of products and supporting collection programs for unused medicines ▶

THE ENVIRONMENTAL FATE OF THE GROUP'S PRODUCTS

OUR ACTIONS (part one)

Internally assessing the Group's products

ECOVAL is a multidisciplinary committee that brings together various experts from within the Group. The role of the committee, which works independently or in collaboration with stakeholders, is to assess products and their environmental impacts. These assessments are carried out as part of filing for new drug marketing approval both in Europe and the United States. Since 2005, the Group has voluntarily assessed the environmental risk for major drugs already on the market.

Working in close collaboration with stakeholders

Sanofi-aventis is confronting the issue of the presence of pharmaceuticals in the environment, **in very low concentrations**, following patient use. The Group is working with stakeholders in the pharmaceutical sector and the academic world to expand scientific knowledge in this area.

The Group is also acquiring essential information through collaborations within the pharmaceutical industry in **Europe** and the United States. The aim of these projects is to assess the potential impact of pharmaceuticals in the environment, including on human health.

In addition, the Group is building partnerships with universities in areas that it believes have not been studied sufficiently, e.g., the efficacy of water treatment with respect to pharmaceuticals, or how pharmaceuticals change in the marine environment.

Furthermore, the Group leads programs to detect and quantify active pharmaceutical ingredients and their degradation products within effluents at its industrial sites. In 2009, three sites were reviewed.

Assessing environmental risk

THE ENVIRONMENTAL FATE OF THE GROUP'S PRODUCTS

OUR ACTIONS (part two)

Promoting the eco-design of products and supporting collection programs for unused medicines

Throughout the product development stages, issues related to health, safety and the environment are part of process optimization to reduce raw material consumption and make processes safer and more environmentally friendly. At the earliest stages of product development, tools are made available to sanofi-aventis employees to allow them to select the reagents and solvents posing the smallest possible hazard. Throughout the development process and during the entire industrial production phase, decisions are made about the processes used, based on economic and HSE criteria, in order to reduce the impact of drug manufacturing. The Group is also pursuing its efforts to reduce the environmental impacts related to packaging, while taking into account current regulatory constraints. In addition, the Group supports local programs for the collection of unused medicines.

► For more information, see website **sanofi-aventis** What to do with your unused medication?

Appendices

SOCIAL AND ENVIRONMENTAL INDICATORS

HOW DATA ARE REPORTED:
METHODOLOGICAL NOTE

STATUTORY AUDITORS' REVIEW REPORT

GLOSSARY

SOCIAL AND ENVIRONMENTAL INDICATORS

The primary sanofi-aventis social and environmental indicators and their variations in recent years are available on the Group's CSR website:



▶ Environmental indicators



▶ Social indicators

HOW DATA ARE REPORTED: METHODOLOGICAL NOTE

SCOPE OF CONSOLIDATION

Social data are consolidated for all Group companies worldwide that are fully consolidated, regardless of their activity (industrial or research sites, commercial affiliates, administrative headquarters), with the exception of Merial⁽¹⁾. At the end of 2009, health and safety data (occupational accidents and injuries) covered the same scope.

Environmental data (including spending and investments) are consolidated for all industrial and research sites. Environmental impact measured as CO₂ emissions from all company vehicles includes all Pharmaceutical Operations affiliates. The environmental impact of administrative headquarters locations is not included within this scope.

Social, health, safety and environmental data are wholly integrated into the scope of consolidation (full data integration).

CHANGES IN SCOPE

Within the Group, changes in scope (new sites, site closings, transfers of activity) between 2008 and 2009 were analyzed according to predefined rules in order to assess Group performance on a scope that is comparable from one period to the next. Detailed information about scope modifications is available at <http://en.sanofi-aventis.com/sustainability/sustainability.asp>

REPORTING GUIDELINES

In order to ensure the uniformity and reliability of indicators used for all entities, the Group implemented standard reporting guidelines covering social factors as well as safety and environmental factors. These documents specify the methodologies to be used for indicator reporting for the entire Group: definitions, methodological principles, calculation formulas and emission factors.

In addition, sanofi-aventis adopted standard data collection tools:

- Social data: In 2008, a new application developed to gather information for the “International Social Report” made it possible to automate a portion of the reporting of the social data collected for all Group entities;
- Safety data: The MSRS system makes it possible to collect safety data for the entire scope;
- Environment: The GREEN tool enabled the consolidation of all data contained in the report.

These tools and guidelines are updated and improved on a regular basis.

ADDITIONAL INFORMATION AND METHODOLOGICAL LIMITS

The methodological principles for certain HSE and social indicators may have limits due to:

- The absence of definitions recognized on a national and/or international level, in particular concerning the different types of employment contracts;
- The necessary estimates and the representative nature of the measurements taken, or the limited availability of external data required for calculations;
- The practical methods used for data collection and entry.

As a result, we make every effort to list the definitions and methodology used for the following indicators and, where appropriate, the confidence limits involved.

(1) Because sanofi-aventis intends to contribute Merial to a joint venture and consequently lose exclusive control (see Note D.8.1 to the consolidated financial statements, page 238 of the 2009 Document de Référence), Merial's data are not reported notwithstanding the fact that on December 31, 2009, Merial was a wholly owned subsidiary of sanofi-aventis. Merial, whose global workforce included 5,601 employees as of December 31, 2009, has approximately 15 industrial sites, 9 research and development sites and a number of administrative offices including its headquarters located in Lyon (France) and Duluth (Georgia, USA).

HOW DATA ARE REPORTED: METHODOLOGICAL NOTE

SAFETY INDICATORS

- Occupational injury with lost time frequency rate (data available on the sanofi-aventis Corporate Social Responsibility website). The frequency rate of occupational lost time injuries is defined as the number of accidents resulting in lost time of one day or more within a 12-month period, per million hours worked. For non-mobile personnel, accidents occurring during the home-workplace commute are not included in this indicator. However, they are included for medical sales representatives, in accordance with the reporting rules defined by the Group. In the event that additional accidents have not yet been recorded at the close of the financial year, or if changes in the qualification of accidents are observed after the financial year has ended, the frequency rate is subsequently corrected.
- Motor vehicle accidents (data available in the Group's 2009 CSR Report and on the sanofi-aventis Corporate Social Responsibility website). Accidents are considered to be motor vehicle accidents if they occur when the driver is at the wheel of the vehicle (driving or parking the vehicle). This concerns all traffic accidents occurring with vehicles owned or leased by the Group or owned by the employee if the vehicle is driven on a regular basis for professional purposes (medical sales representatives).

ENVIRONMENTAL INDICATORS

- CO₂ emissions (data available on the sanofi-aventis Corporate Social Responsibility website). Direct emissions are calculated on the basis of data from the Greenhouse Gas Protocol Initiative in relation to fuel emission factors. Indirect emissions resulting from other energy sources purchased off-premises are assessed on the basis of specific emission factors per site. Those resulting from drug product transport are not included in this total. Other greenhouse gas emissions are not significant compared to those of CO₂. Emissions resulting from pharmaceutical sales fleet vehicles (medical representatives) were estimated on the basis of fuel consumption using a reporting system that distinguishes the emission factor specific to the type of fuel consumed (gasoline or diesel).
- Percentage of renewable electricity (data available on the sanofi-aventis Corporate Social Responsibility website). The percentage of renewable electricity compared to total purchased is calculated on data based on the electrical source in each country where the Group operates, according to International Energy Agency (IEA) data.
- Volatile Organic Compound emissions (VOCs) (data available in the Group's 2009 CSR Report and on the sanofi-aventis Corporate Social Responsibility website). VOCs are estimated either on the basis of the mass balance or by direct measurement; the uncertainty resulting from these estimates is on the order of 10%.
- Wastewater discharge (data available in the Group's 2009 CSR Report and on the sanofi-aventis Corporate Social Responsibility website). Data corresponds to waste after internal or external treatment. In the event of a lack of information about external treatment, a purification rate of 50% is assumed.
- Waste (data available in the Group's 2009 CSR Report and on the sanofi-aventis Corporate Social Responsibility website). The distinction between hazardous and non-hazardous waste corresponds to that used in European regulations for European Union member countries (Decision 2000/532/EC of May 3, 2000) and that used in local regulations for other countries. It is noted that waste from remediation activities is not included in the published operational total.

CONSOLIDATION AND INTERNAL CONTROLS

The Corporate HR and HSE Departments are responsible for ensuring that all data are consolidated on the basis of information provided by the industrial and research sites and Group affiliates or administrative headquarters throughout the world. When sites include more than one function, the one with the greatest environmental impact is taken into account. HSE coordinators for each activity perform an initial validation of safety and environmental data prior to their consolidation. Corporate HR and HSE also verify data consistency during consolidation.

HOW DATA ARE REPORTED: METHODOLOGICAL NOTE

These validations include data comparisons from previous years as well as careful analysis of any significant discrepancies. Social data regarding the workforce are compared with consolidated data in the management control database. To ensure that site representatives have properly understood the HSE indicators, and to ensure that the data reported correspond with those requested, HSE data verification is carried out during in-house audits conducted at Group sites.

EXTERNAL CONTROLS

In order to obtain an external review of our data's reliability and the thoroughness of our reporting procedures, we asked our Statutory Auditors to perform specific verification of certain CSR information and data, identified by an asterisk and available in the 2009 sanofi-aventis CSR Report or on the Group's CSR website. The review performed by the Statutory Auditors was expanded this year to encompass information concerning the implementation of the Group's CSR approach, with particular focus on the following areas: stakeholder consultation, ethics in research, ethical business conduct, access to medicines, pharmacovigilance, occupational health, diversity and the environmental management system. The information covered by this work is also identified by an asterisk and may be found in the sanofi-aventis 2009 CSR Report or on the Group's CSR website.

The Statutory Auditors' assurance statement, describing the work they performed as well as their comments and conclusions, appears in the 2009 sanofi-aventis CSR Report as well as on the Group's CSR website (section: Statutory Auditors' Review Report). In addition, in accordance with the NRE Law, selected HSE and social data published in the 2009 CSR report were specifically reviewed by the Statutory Auditors in accordance with the relevant legislation and French professional standards to ensure that this information is consistent with the management report ("environmental data" and "social data" paragraph in the management report).

Lastly, a pre-audit of the Group's approach was conducted in order to identify and quantify the direct and indirect sources of greenhouse gas emissions including third-party emissions. The purpose of the pre-audit was to have a critical external view of the scope, tools and methodologies used by the Group.

STATUTORY AUDITORS' REVIEW REPORT ON A SELECTION OF CORPORATE SOCIAL RESPONSIBILITY (CSR) INFORMATION AND DATA

This is a free translation into English of the Statutory Auditors' Report issued in the French language and is provided solely for the convenience of English-speaking readers. This report should be read in conjunction with, and construed in accordance with French law and professional auditing standards applicable in France.

At sanofi-aventis' request and in our capacity as Statutory Auditors for sanofi-aventis, we have performed a review designed to provide moderate assurance on a selection of information and data relating to fiscal year 2009 published in the sanofi-aventis Group's Corporate Social Responsibility Report ("CSR Report") and identified by an asterisk ("information" and "data").

The sanofi-aventis Corporate Social Responsibility Division was responsible for preparing the information and data contained in the CSR Report in accordance with the Group's reporting procedures applicable during 2009, which are available at the Group's headquarters and summarized in the section "How data are reported: methodological note" of the CSR Report. Our responsibility is to express a conclusion on the selection of information and data based on our review.

NATURE AND SCOPE OF OUR PROCEDURES

We planned and performed the procedures set out below to obtain moderate assurance as to whether the information and data are free of material misstatements. A higher level of assurance would have required more extensive procedures.

For the CSR information covered by our procedures:

- We reviewed the content described in the CSR Report in order to identify information relative to the Group's accomplishments in the implementation of its CSR approach, in particular concerning the following areas: stakeholder consultation, ethics in research, ethical business conduct (human rights, corporate governance, the fight against corruption, responsible marketing, supplier relations, clinical trials), access to medicines, pharmacovigilance, occupational health, diversity and the environmental management system.
- We conducted interviews with:
 - The Sustainability Department, which is in charge of implementing the CSR approach;
 - Individuals involved in implementing the approach in cross-functional departments such as human resources, purchasing and internal controls;
 - Individuals in departments such as Medical Affairs, R&D, Access to Medicines and HSE that are involved with CSR implementation;
 - The outside firm that assisted the Group with stakeholder consultation.
- We obtained supporting documentation such as internal procedures, minutes of committee meetings and other meetings, teaching materials, studies, questionnaires (for suppliers and stakeholders) and the survey findings that made it possible to support the selected information.

For the data covered by our procedures:

- We assessed Group reporting procedures with regard to their consistency, relevance, reliability, neutrality and understandability.
- At the Group level, we performed analytical procedures and verified, on a random basis, the calculations and data consolidation. This work was based specifically on interviews with the individuals responsible for the preparation and application of the reporting procedures as well as for data consolidation (HSE Department).
- We selected a sample of industrial and research sites (Swiftwater IO, Vertolaye, Vitry) and Pharmaceutical Operations in four countries (United States, France, Mexico and Japan). This selection was made on the basis of quantitative and qualitative criteria applied to the data (such as their relative contribution, geographic area and function) and on the basis of work conducted in prior years. Based on interviews with the individuals responsible for data preparation at the selected sites and units, we verified the understanding and application of procedures and carried out detailed tests to verify the calculations made and reconcile the data with the supporting documentation.

STATUTORY AUDITORS' REVIEW REPORT ON A SELECTION OF CORPORATE SOCIAL RESPONSIBILITY (CSR) INFORMATION AND DATA

The contribution of these entities to the Group consolidated total is:

- 33% of Volatile Organic Compound (VOC) emissions;
- 22% of direct CO₂ and 13% of indirect CO₂ emissions;
- 18% of the workforce (to calculate the lost time injury frequency rate).

In performing our review, we were assisted by our specialized sustainability team.

Note concerning the publication of information on Internet: Our procedures did not include any review of information that was updated after the original date of publication (May 7, 2010) of this information in the CSR Report.

INFORMATION ON PROCEDURES

The Group presented detailed information on the methodologies used for reporting information and data in the section entitled "How data are reported: methodological note" and in the comments on the published information and data. Any methodological limits inherent to the reporting of certain indicators have been disclosed.

CONCLUSIONS

Based on our review, nothing has come to our attention that causes us to believe:

- That the selected information is not consistent with the collected supporting documentation;
- That the selected data has not, in all material respects, been prepared in accordance with the Group's reporting procedures applicable during the 2009 fiscal year.

Neuilly-sur-Seine (France), May 7, 2010

The Statutory Auditors

PricewaterhouseCoopers Audit

Ernst & Young Audit

Catherine Pariset

Philippe Vogt

Christian Chiarasini

Jacques Pierres

GLOSSARY

AA1000: Accountability series and standards	ICH: International Conference on Harmonization
AACME: American Academy of Continuing Medical Education	IFPMA: International Federation of Pharmaceutical Manufacturers & Associations
ADA: American Diabetes Association	ILAR: Institute for Laboratory Animal Research
AFEP: French Association of Private Companies	ILO: International Labor Organization
ALDEE: <i>Actions Locales de Développement Économique et d'Échanges</i> (local actions for business development and exchange)	INTERPOL: INTERnational POLice
AMM: Marketing authorization	ISO: International Organization for Standardization
ASCO: American Society of Clinical Oncology	LEEM: The French Pharmaceutical Companies Association
BCR: Binding Corporate Rules	MEDEF: <i>Mouvement des Entreprises de France</i> (French employers association)
BLIHR: Business Leaders Initiative on Human Rights	MHLW: Ministry of Health, Labor and Welfare
BTS: <i>Brevet de Technicien Supérieur</i> (French postsecondary technical certificate)	MMV: Medicines for Malaria Venture
CEFIC: European Chemical Industry Council	MSR: Medical Sales Representatives
CFR21: Code of Federal Regulations, title 21, Food and Drugs	MSRS: Monthly Safety Reporting System
CMO: Chief Medical Officer	MWh: Megawatt hour
CNAC: National Anti-Counterfeit Committee	NGO: Non-Governmental Organization
CNIL: French national data protection authority	NOx: Nitrogen Oxides
CO₂: Carbon Dioxide	NRE: <i>Nouvelles Régulations Économiques</i>
COD: Chemical Oxygen Demand	OECD: Organization for Economic Cooperation and Development
CPP: <i>Comité de Protection des Personnes</i> (French independent ethics review board)	OFR: Operating and Financial Review
CSR: Corporate Social Responsibility	PACA: <i>Provence-Alpes-Côte d'Azur</i> (region of France)
DNDi: Drugs for Neglected Diseases initiative	PACT+™: Providing Access to Cancer Therapy
EACCME: European Accreditation Council for Continuing Medical Education	PAP: Patient Assistance Programs
edH: <i>Entreprises pour les droits de l'Homme</i> (Businesses for Human Rights)	PMDA: Pharmaceuticals and Medical Devices Agency (Japan)
EEA: European Economic Area	PhRMA: Pharmaceutical Research and Manufacturers of America
EFPIA: European Federation of Pharmaceutical Industries and Associations	PPA: Prescription Assistance Program
EMA: European Medicines Agency	PSI: Pharmaceutical Security Institute
EPEAT: Electronic Product Environmental Assessment Tool	QBPC: Quality Brands Protection Committee
ESC: European Society of Cardiology	R&D: Research and Development
FDA: Food and Drug Administration	SME: Small and medium size enterprises
GCP: Good Clinical Practices	SOPRAN: Society for the Promotion of New Activities (a sanofi-aventis affiliate)
GPEC: Workforce Planning Agreement	SOX: Sarbanes-Oxley Act
GRI: Global Reporting Initiative	SOx: Sulfur Oxides
GSC: Group Sustainability Committee	SPC: Summary of Product Characteristics
HIV: Human Immunodeficiency Virus	UFAW: Universities Federations for Animal Welfare
HR: Human Resources	VIE: Corporate volunteer program
HSE: Hygiene, Safety, Environment	VOCs: Volatile Organic Compounds
	WHO: World Health Organization

Sanofi-aventis

174, avenue de France

75013 Paris – France

Tel.: +33 1 53 77 40 00

<http://en.sanofi-aventis.com/sustainability/sustainability.asp>

Contact: developpementdurable@sanofi-aventis.com

Photography credits:

Cover (from left to right): Ned Frisk/Blend Images/Corbis; Image Source/Getty Images; BLOOMimage/Getty Images; Lane Oatey/Getty Images; Plush Studios/Blend Images/Corbis; BLOOMimage/Corbis; Rubberball/Getty Images; BreBa/Beyond/Corbis; Image Source/Corbis; George Doyle/Stockbyte/Getty Images; Rubberball/Getty Images; Kristy-Anne Glubish/Design Pics/Corbis; Rubberball/Getty Images;

Photodisc/Getty Images; Rubberball/Getty Images

p.3 (from top to bottom): Marthe Lemelle and P. Allan – Kura Images / Corbis – p.13 (from top to bottom): Gil Corre; Gil Corre; Dung Vo Trung/Interlinks Image; Renzo Gosteli / Rapho – p.15: Gil Corre p.16: Peter Blakely / Interlinks Image – p.17 (from top to bottom): William Beaucardet/ PWP; Eric Larrayadieu/Interlinks Image; Denis Félix/Corbis – p.19: Didier Robcis/Interlinks Image – p.20: Mireille Cayre

p.21 (from top to bottom): Denis Félix/Interlinks; MedicalRF.com/BSIP; sanofi-aventis, US – p.22: Romain Baltz – p.23 (from top to bottom): Eric Larrayadieu/Interlinks Image; Gil Corre; Graeme Williams/ Interlinks Image – p.25 (from top to bottom): Didier Robcis/Interlinks Image; Dung Vo Trung/Interlinks Image; Eric Larrayadieu/Interlinks Image – p.27: Gil Corre

p.28 (from top to bottom): John Foxx/Stockbyte Silver/Getty Images; Jean-Erick Pasquier/Rapho; Gil Corre – p.35: Franck Parisot

p.36 (from top to bottom): Evelyn Hockstein/Interlinks Image; Concorde Proderam; Alain Buu/Interlinks Image – p.37 (from top to bottom); Concorde Proderam; Alain Buu/Interlinks Image

p.38 (from top to bottom): Eric Audras/PhotoAlto/Corbis; William Beaucardet/PWP; Marie Simonnot & Martin Rocher

p.41 (from top to bottom): John Foxx/Stockbyte Silver/Getty Images-Andersen Ross/ Stockbyte/Getty Images; Denis Félix/Interlinks Image – p.42 Gil Corre – p.45 (from top to bottom): Denis Félix/Interlinks Image; Gérard Uféras/Rapho; Renzo Gosteli/Rapho – p.46: Gil Corre – p.47 (from top to bottom): Franck Parisot; Masterfile; Hubert Mouillade – p.48: Marthe Lemelle – p.49 (from top to bottom): William

Beaucardet/PWP; William Beaucardet/PWP

p.55 (from top to bottom): Denis Félix/Interlinks Image; MediImages/Getty Images; Renzo Gosteli/Rapho

p.58 (from top to bottom): Pascal Barollier; Gérard Uféras/Rapho; Background Photo Collection

p.61 (from top to bottom): James Lauritz/Digital Vision/Getty Images; Jan Spijkers/Ad Mission; Franck Parisot – p.63: Marthe Lemelle

p.64 (from top to bottom): Dung Vo Trung/Interlinks Image; Ryan McVay/Photodisc/Getty Images; William Beaucardet/PWP

p.68 (from top to bottom): Johann Rousselot/Rapho; Ryan McVay/Photodisc/Getty Images.

The Report was designed and produced by the sanofi-aventis CSR-Sustainability Department and Corporate Communications,

Euro RSCG C&O and Bee-Buzziness with the participation of Deloitte and the writers Florence Boniface and Eric Gorgeu.

It was translated from the French by Mary Shaffer and Terry Ascencio-Parvy.

We wish to thank all those who contributed to creating this report.

This report contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in Research and Development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2009. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Product indications described in this report are composite summaries of the major indications approved in the product's principal markets. Not all indications are necessarily available in each of the markets in which the products are approved. The summaries presented herein for the purpose of the review do not substitute for careful consideration of the full labelling approved in each market.